: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, January 2026
Free Subscription

Abstracts
Retrieve all available abstracts of the following 561 articles:
HTML format

Single Articles

YANG CY, Ho SC, Chiu YW, Weng YH, et al
Risk of death from bladder cancer in relation to long-term exposure to fine particulate air pollution in Taiwan.
J Toxicol Environ Health A. 2026 Jan 2:1-10. doi: 10.1080/15287394.2025.2611423.
Abstract

YAMAMOTO H, Oura S
Possible Differentiation Between Recurrent Lymph Nodes of Bladder Cancer and Malignant Lymphoma on Ultrasound: A Case Report.
Cureus. 2025;17:e98260.
Abstract

SIKDER RK, Ellithi M, Uzzo RN, Weader DJ, et al
Editor's Note: Differential Effects of Clinically Relevant N- versus C-Terminal Truncating CDKN1A Mutations on Cisplatin Sensitivity in Bladder Cancer.
Mol Cancer Res. 2026;24:84.
Abstract

ANWAR I, Pandith AA, Rasool SUA, Manzoor U, et al
Promoter hypermethylation drives a paradoxical up regulation of hTERT with prognostic implications in bladder cancer.
Urol Oncol. 2025 Dec 31:110963. doi: 10.1016/j.urolonc.2025.
Abstract

SORIA F, Liedberg F, Stahl E, Dominguez-Escrig JL, et al
Perioperative and Oncological Outcomes of Distal Ureterectomy for Upper Tract Urothelial Carcinoma (UTUC): A Multicentre Study from the European Association of Urology Non-muscle-invasive Bladder Cancer/UTUC Guidelines Panels with a Focus on Survival
Eur Urol Oncol. 2025 Dec 31:S2588-9311(25)00328.
Abstract

LEE J, Jung H, Kim EG, Ahn J, et al
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer.
Sci Adv. 2026;12:eady0041.
Abstract

JURCZOK N, Dernbach G, Ebner B, Plage H, et al
Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer.
Eur Urol Oncol. 2025 Dec 30:S2588-9311(25)00333.
Abstract

BIDI S, Nerli RB, Rangrez S, Ghagane SC, et al
Association of SLC14A1C/T Polymorphisms in Patients with Bladder Cancer in Comparison with Healthy Controls.
South Asian J Cancer. 2025;14:810-814.
Abstract

SPITZER A, Aupperle-Lellbach H, Spitzer M, Weidle S, et al
DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.
Vet Sci. 2025;12:1209.
Abstract

WOLF I, Giess N, Roider C, Schultze-Seemann S, et al
Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy.
Molecules. 2025;30:4802.
Abstract

KAYER A, Ozen A, Dinleyici EC
Urinary Microbiota Composition in Treatment-Naive Bladder Cancer: A Case-Control Study with Tumor Invasiveness Stratification.
Medicina (Kaunas). 2025;61:2240.
Abstract

SONG B, Lee H, Lee S, Hong SK, et al
Preoperative serum albumin level is associated with postoperative short- and long-term renal function deterioration in patients who underwent radical cystectomy for bladder cancer.
Investig Clin Urol. 2026;67:24-31.
Abstract

CERRATO C, Pandolfo SD, Kraft P, Ko DSC, et al
Opportunistic salpingectomy during radical cystectomy for bladder cancer: A systematic review of the literature.
Asian J Urol. 2025;12:471-477.
Abstract

ANIS O, Bar V, Zundelevich A, Anil SM, et al
Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich Cannabis sativa strains.
Asian J Urol. 2025;12:534-543.
Abstract

LAYMON M, Elsawy AA, Elsorougy A, Hashem A, et al
Clinically lymph node-positive urothelial bladder cancer treated with upfront radical cystectomy: Diagnostic accuracy of MRI and long-term oncologic outcomes.
Asian J Urol. 2025;12:520-528.
Abstract

SONG M, Ren H, Wang L, Zhou Y, et al
Beyond VI-RADS Uncertainty: Leveraging Spatiotemporal DCE-MRI to Predict Bladder Cancer Muscle Invasion.
Bioengineering (Basel). 2025;12:1338.
Abstract

CIGLIOLA A, Maiorano BA, Dengur D, Tateo V, et al
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
Cancers (Basel). 2025;17:4017.
Abstract

PLAGE H, Biernath N, Furlano K, Weinberger S, et al
Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes.
Cancers (Basel). 2025;17:3990.
Abstract

HOSHI S, Meguro S, Makabe S, Onagi A, et al
Immunosuppressive Role of Integrin beta8 in Recurrence After Bacillus Calmette-Guerin (BCG) Therapy for Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025;17:3964.
Abstract

XIAO B, Zeng Q, Peng X, He Q, et al
An interpretable machine learning model based on CT imaging for predicting lymphovascular invasion and survival in bladder urothelial carcinoma: a multicenter study.
BMC Med Imaging. 2025;25:513.
Abstract

LI C, Meng F, Lu C, Li A, et al
A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.
J Nanobiotechnology. 2025 Dec 29. doi: 10.1186/s12951-025-03935.
Abstract

YANG CW, Yen CH, Chien TM, Yu SY, et al
Excavatolide E triggers oxidative stress-associated apoptosis and DNA damage to inhibit bladder cancer cell proliferation.
Mol Biol Rep. 2025;53:234.
Abstract

LI L, Ren F, Liu Z, Tian X, et al
Urothelial carcinoma following kidney transplantation: a narrative review of Chinese insights and challenges from pathogenesis to precision diagnosis and treatment.
Front Immunol. 2025;16:1668356.
Abstract

HO PARK J, Lee H, Lee S, Hong SK, et al
Effect of early detubularization on urethro-intestinal anastomosis during robot-assisted radical cystectomy and intracorporeal neobladder among bladder cancer patients.
Front Oncol. 2025;15:1680595.
Abstract

KANEMOTO S, Yamamoto S, Hino K, Tsuboi K, et al
Multiple Bone Metastases From Non-Muscle Invasive Bladder Cancer Responding to Combination Therapy With Enfortumab Vedotin and Pembrolizumab: A Case Report.
IJU Case Rep. 2025;9:e70119.
Abstract

PENUNURI A, Greenberg E, Phillips J, Katims AB, et al
The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.
Curr Urol Rep. 2025;27:3.
Abstract

XU M, Yue S, Chen Z, Li R, et al
hsa-miR-145-3p defines a fibro-inflammatory bladder cancer subtype with distinct therapeutic vulnerabilities.
Discov Oncol. 2025 Dec 28. doi: 10.1007/s12672-025-04355.
Abstract

WANG Y, Xue H, Xu S, Qin Y, et al
Network toxicology analysis of hair dye components and their association with breast and bladder cancers.
Afr J Reprod Health. 2025;29:204-216.
Abstract

AHMADI SP, Sadabadi F, Khoshbin B, Sheikhi Z, et al
Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study.
BMC Urol. 2025 Dec 28. doi: 10.1186/s12894-025-02006.
Abstract

MOUSA MMA, Abou-Dobara MI, El-Zahed MM, El-Sherif ME, et al
Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.
BMC Microbiol. 2025 Dec 27. doi: 10.1186/s12866-025-04572.
Abstract

ZHONG MY, Zou XC, Chen PH
Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy.
Discov Oncol. 2025 Dec 27. doi: 10.1007/s12672-025-04275.
Abstract

ZHANG M, Chen C, Zeng X, Zhao Q, et al
Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer.
Abdom Radiol (NY). 2025 Dec 27. doi: 10.1007/s00261-025-05358.
Abstract

TAN J, Wang Y, Huang J, Dong B, et al
Exploration of the Prognostic Value of PANoptosis-Related Genes in Bladder Cancer.
Am J Mens Health. 2025;19:15579883251404985.
Abstract

HU Z, Zeng D, Zhao X, Luo Y, et al
Global Disparities and Temporal Trends in Prostate, Bladder, and Kidney Cancer Burden Among Men: A Systematic Analysis of 204 Countries (1990-2021).
Cancer Control. 2025;32:10732748251411011.
Abstract

HUANG J, Chen D, Ji G, Ma J, et al
ERO1A promotes the proliferation, migration and invasion of bladder cancer through ALOX5 mediated activation of JAK-STAT signaling pathway.
J Transl Med. 2025;23:1427.
Abstract

NAIR MS, Scarborough J, Reddy CA, Bommireddy AR, et al
Trimodality Therapy for Bladder Cancer: A Single Institution Retrospective Analysis of Factors Associated With Outcomes for High-Risk Patients Undergoing Organ-Sparing Therapy.
Clin Genitourin Cancer. 2025;24:102477.
Abstract

OLUMOYIN K, El Naqa L, Rejniak K
Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data.
ArXiv [Preprint]. 2025 Dec 17:arXiv:2512.15706.
Abstract

HANLON T, D'Andrea VD, Stelter I, Bekele R, et al
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization.
Bladder Cancer. 2025;11:23523735251409720.
Abstract

XUE Z, Qie Y, Shen C, Wu Z, et al
Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
Cancer Sci. 2025 Dec 24. doi: 10.1111/cas.70311.
Abstract

LV J, Li K, Zhou J, Yu R, et al
Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin.
J Exp Clin Cancer Res. 2025;44:324.
Abstract

ROESSLER N, Miszczyk M, Gontero P, Miyajima K, et al
Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.
World J Urol. 2025;44:65.
Abstract

LIU S, Liu T, Yang C, Mou Z, et al
Cytoskeletal protein KRT14 governs cisplatin resistance by modulating eIF4H-dependent ACOX2 translation and lipid metabolism in bladder cancer.
Cell Death Dis. 2025 Dec 24. doi: 10.1038/s41419-025-08369.
Abstract

LIU H, Jiang X, Wang T, Zhang G, et al
Low-dose corticomedullary phase CT urography with artificial intelligence iterative reconstruction for bladder cancer evaluation.
Br J Radiol. 2025 Dec 24:tqaf315. doi: 10.1093.
Abstract

PEKER P
Correspondence regarding "Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guerin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German healt
World J Urol. 2025;44:64.
Abstract

VANTAGGIATO L, Frisenda M, Shaba E, Splendore C, et al
Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Stage-Specific Molecular Signatures and Prognostic Biomarkers.
Proteomes. 2025;13:65.
Abstract

SILVANI C, Santangelo A, Considine J, Tylecki A, et al
Incarcerated Patients Present with More Advanced Bladder Cancer Stage: A Statewide Analysis.
Urol Pract. 2025 Dec 24:101097UPJ0000000000000961.
Abstract

CARROLL TF, Bardot JP, David J, Zucker M, et al
Compliance with Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer.
Urol Pract. 2025 Dec 24:101097UPJ0000000000000962.
Abstract

OZGUN G, Alexander A, Arbour G, Kollmannsberger C, et al
Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.
Curr Oncol. 2025;32:699.
Abstract

HU K, Ma X, Luo L, Li P, et al
FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.
J Immunother. 2025 Dec 26. doi: 10.1097/CJI.0000000000000595.
Abstract

MIYAJIMA K, Matsukawa A, Yanagisawa T, Miszczyk M, et al
Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Open Sci. 2025;83:54-63.
Abstract

JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
Bladder Cancer Burden in the USA: Population Scenarios for 2040.
Eur Urol Open Sci. 2025;83:99-108.
Abstract

ZHUANG J, Yu H, Cao Q, Bai R, et al
Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
Eur Urol Open Sci. 2025;83:36-45.
Abstract

XIANG J, Luo Y, Zhang B, Ke K, et al
Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy.
Front Oncol. 2025;15:1670574.
Abstract

ZHANG J, Wang Y, Yan Q, Wang H, et al
SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
Front Immunol. 2025;16:1708324.
Abstract

HAN Y, Peng J, Yan W, Wu Z, et al
FLLL31 Induces Apoptosis via the FOXO4/BCL6 Axis to Inhibit Bladder Cancer Progression.
Hum Mutat. 2025;2025:5947612.
Abstract

CHEN J, Fu Y, Zhang Z, Zhao J, et al
Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.
Int J Nanomedicine. 2025;20:15235-15275.
Abstract

GONG J, Sun D, Zheng Y, Mao C, et al
Dauricine Inhibits Macrophages M2 Polarization and Regulates the Progression and Ferroptosis via HCK/IDO1 in Urinary Bladder Cancer.
Food Sci Nutr. 2025;13:e71341.
Abstract

CHEN D, Li Z, Sui Y, Zeng Y, et al
The efficacy and safety of interval and post-reTURBT intravesical therapy for bladder cancer.
iScience. 2025;28:114152.
Abstract

LI Q, Chen QF, Liao NQ
Graph Neural Network-Based Multi-Scale Whole Slide Image Fusion for pT Staging of Muscle-Invasive Bladder Cancer.
Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70292.
Abstract

LI M, Liu T, Shi J, Zhou F, et al
USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer.
J Exp Clin Cancer Res. 2025 Dec 23. doi: 10.1186/s13046-025-03621.
Abstract

ZHI L, Yuan L
Alantolactone curbs the malignant progression of bladder cancer partly via the HSP90AB1/LRP5/beta-catenin axis.
Mamm Genome. 2025;37:20.
Abstract

GOUHIZOUN O, Pattou M, Guena F, Khaddad A, et al
Diagnostic accuracy of [18F]-FDG-PET/CT for lymph node staging in bladder cancer prior to radical cystectomy.
World J Urol. 2025;44:59.
Abstract

D'ALESSIO I, Siloche D, Civilini E, Bissacco D, et al
Aortic complications after treatment with bacillus Calmette-Guerin: a tertiary hospital experience and an update of the literature.
J Cardiovasc Surg (Torino). 2025;66:532-542.
Abstract

DONG W, Bi J, Liu H, Yan D, et al
Correction: Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.
Mol Cancer. 2025;24:309.
Abstract

WANG C, Li K, Wan S, Chen S, et al
TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.
Cell Death Dis. 2025;16:923.
Abstract

YANG H, Liu X, Nie J, Wu S, et al
USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer.
Cell Death Dis. 2025 Dec 23. doi: 10.1038/s41419-025-08297.
Abstract

ZHAO X, Liu H, Wang C, Guo F, et al
Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
Front Genet. 2025;16:1615167.
Abstract

LING Z, He S, Li T, Zhang J, et al
Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy.
Hum Mutat. 2025;2025:5569005.
Abstract

WENG R, Phung TAT, Bell R, Dyrskjot L, et al
Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancer.
BJUI Compass. 2025;6:e70131.
Abstract

MARTEL A, Raue L, Avogbe PH, Raisch J, et al
Urinary biomarkers in multicentric studies: Shaping the future of bladder cancer diagnosis and follow-up.
BJUI Compass. 2025;6:e70124.
Abstract

LI C, Lv G, Xiong Z, Wang Z, et al
Ginsenoside Rh2 Suppresses the Fanconi Anemia Pathway by Inhibiting NF-kappaB-Mediated FANCL Transcription in Bladder Cancer.
Dose Response. 2025;23:15593258251411761.
Abstract

DI SPIRITO A, Zuccolotto G, Tosi A, Balkhi S, et al
Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.
Front Cell Dev Biol. 2025;13:1719978.
Abstract

WANG JM, Xie HY, Zhang FH, Shu X, et al
Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization.
J Hematol Oncol. 2025;18:110.
Abstract

JANENZ J, Leipe A, Urban N, Schaefer M, et al
Activation of TRPV3 channels in bladder cancer cells stimulates ATP release.
Mol Pharmacol. 2025;108:100096.
Abstract

LI G, Tatarano S, Yoshino H, Saito S, et al
Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.
Mol Oncol. 2025 Dec 21. doi: 10.1002/1878-0261.70187.
Abstract

JAZAYERI SB, DiNatale RG, Guske C, Harrs C, et al
Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design.
Eur Urol Focus. 2025 Dec 19:S2405-4569(25)00367.
Abstract

JIANG L, Ge W, Feng R, Ji L, et al
Innovative AI model for bladder cancer diagnosis.
Discov Oncol. 2025 Dec 20. doi: 10.1007/s12672-025-04278.
Abstract

SHI C, Xu J, Chen Q, Gao X, et al
Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma.
Clin Epigenetics. 2025;17:204.
Abstract

XU C, Ying W, He Y, Wu Y, et al
Vitamin C enhances cisplatin sensitivity in bladder cancer via 5hmC-mediated epigenetic modulation of ATF4.
Clin Epigenetics. 2025;17:203.
Abstract

JIANG Y, Xu C, He W, Zhang C, et al
First-line therapies analysis in advanced/metastatic urothelial carcinoma: prognostic insights in ADCs combined therapy with propensity score analysis and RNA-Seq.
Int Immunopharmacol. 2026;169:116060.
Abstract

MAIORANO BA, Cigliola A, Tateo V, Mercinelli C, et al
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.
ESMO Open. 2025;10:105862.
Abstract

GALSKY MD, Gschwend JE, Milowsky MI, Schenker M, et al
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.
Ann Oncol. 2026;37:69-78.
Abstract

CAINI S, Cosma C, Aprea MC, Saieva C, et al
Heavy metals levels in pre-diagnostic serum of nonsmokers with cancer of the lung, bladder and prostate, and paired individuals.
Arch Environ Occup Health. 2025;80:303-307.
Abstract

SHAMSEDDINE A, Abbas N, Temraz S, Al Darazi M, et al
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01).
Future Oncol. 2025;21:3873-3884.
Abstract

PANER GP, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.
Adv Anat Pathol. 2026;33:1-16.
Abstract

WAI R, Sheahen B, Thomas B
Severe itch from miliaria managed with propantheline: a case report.
BMJ Support Palliat Care. 2025;16:85-87.
Abstract

HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
J Clin Med. 2026;15:338.
Abstract

TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
Int J Mol Sci. 2026;27:476.
Abstract

NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
Int J Mol Sci. 2025;27:238.
Abstract

JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
Diagnostics (Basel). 2025;16:69.
Abstract

JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2025;18:136.
Abstract

WU Z, Zeng J, Feng L, Zhu X, et al
Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
Abstract

ADMIRE K, Gegick S
Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
BMJ Case Rep. 2026;19:e268157.
Abstract

RAGHAVAN D
Sad But True: Inconsistent Care for Invasive Bladder Cancer.
JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
Abstract

YANG FH, Zhang W, Wang R, Mao S, et al
Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
Abstract

GATELLIER L, Nakata K
Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
Jpn J Clin Oncol. 2026;56:115-116.
Abstract

ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
Ann Med. 2026;58:2612387.
Abstract

SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
[Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
Abstract

REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
Radiat Oncol. 2026;21:8.
Abstract

XU D, Jacob JJ, Wieczorek K, Wang L, et al
Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
Abstract

WANG H, Xiong Y, He T, He M, et al
MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
Abstract

WANG J, Lu Q, Jiao P, Jian J, et al
Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
Cancer Med. 2026;15:e71477.
Abstract

HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
J Cancer Res Clin Oncol. 2026;152:35.
Abstract

JIN Z, Yang W, Peng Y, Ma L, et al
HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
FASEB J. 2026;40:e71388.
Abstract

BAI R, Cai L, Jiang M, Wang C, et al
Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
Abstract

DAI P, Chen L, Dong Z, Wang H, et al
LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
Abstract

SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
Abstract

SAOULI A, Contieri R, Quhal F, Hurle R, et al
Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
Abstract

LI X, Xie J, Song SJ, Ahlquist CSE, et al
Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
Abstract

CELLULAR LONGEVITY OMA
RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
Oxid Med Cell Longev. 2025;2025:9894089.
Abstract

PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
Machine-learning-based determination of sex-related bladder cancer biomarkers.
bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
Abstract

FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
Arch Ital Urol Androl. 2025;97:14467.
Abstract

BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
Arch Ital Urol Androl. 2025;97:14596.
Abstract

SHI G, Zhou X, Yang F, Wang T, et al
Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
Am J Mens Health. 2026;20:15579883251410519.
Abstract

PATTOU M, Robert G, Gouhizoun O, Guena F, et al
Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
World J Urol. 2026;44:77.
Abstract

YUAN J, Yu S, Zheng J
Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
Chin Clin Oncol. 2025;14:71.
Abstract

FU Q, Yan F, Sun Z, Yao Z, et al
Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
Arch Esp Urol. 2025;78:1493-1500.
Abstract

ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
Arch Esp Urol. 2025;78:1392-1400.
Abstract

ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
Advances in the management of localized bladder cancers.
Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
Abstract

ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
World J Urol. 2026;44:76.
Abstract

[Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
Abstract

HE K, Lin C, Wang H, Wu H, et al
The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
Exp Cell Res. 2026;455:114885.
Abstract

MINATO A, Jojima K, Watanabe S, Sugita Y, et al
Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
Cancer Diagn Progn. 2026;6:135-143.
Abstract

ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
J Robot Surg. 2026;20:151.
Abstract

CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
J Biomed Sci. 2026;33:2.
Abstract

MAY M, Wolff I, Brookman-May S, Burger M, et al
Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
Abstract

SAITO M, Kakoi N, Izumi M, Aoki H, et al
[A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
Hinyokika Kiyo. 2025;71:425-428.
Abstract

WANG Y, Liu H, Wang T, Yang Y, et al
GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
Exp Cell Res. 2026;455:114884.
Abstract

GUO C, Zhou Y, Liu X, Gao K, et al
Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
Abstract

LI Y, Zhao B, Gao W, Wu Y, et al
Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
Clin Exp Med. 2026;26:62.
Abstract

BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
J Cancer Res Clin Oncol. 2026;152:26.
Abstract

STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
Nat Commun. 2025;17:334.
Abstract

LIU P, Zhang L, Zhou Q, Fu Z, et al
STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
Chem Biol Interact. 2026;424:111866.
Abstract

YE Y, Chen Q, Huang Z, Huang Q, et al
Preferred surgical strategies for bladder diverticular carcinoma.
Sci Rep. 2025;16:917.
Abstract

PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
Arch Ital Urol Androl. 2025;97:14167.
Abstract

YU EM, Linville L, Hwang MW, Kim Y, et al
Harnessing genomic profiling for improved urothelial cancer outcomes.
Expert Rev Anticancer Ther. 2026;26:93-104.
Abstract

ZHANG T, Zhang X, Qian L, Hu C, et al
Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
Biomol Biomed. 2025;26:711-719.
Abstract

DIANA P, Gallioli A, Uleri A, Mas L, et al
Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
Actas Urol Esp (Engl Ed). 2026;50:501830.
Abstract

CHENG AV, Bardell J, Sangoi AR
Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
Int J Surg Pathol. 2026;34:201-206.
Abstract

HISANAGA E, Sano T, Yokoo H
Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
Intern Med. 2026;65:183-186.
Abstract

KAYAR K, Dogan MB, Karabay E
A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
Int J Surg Pathol. 2026;34:158-161.
Abstract

KASUKAWA S, Kametaka H, Makino H, Fukada T, et al
[A Case of Pelvic Abscess Treated with Transperineal Drainage for Lower Gastrointestinal Perforation in Terminal Cancer].
Gan To Kagaku Ryoho. 2025;52:1189-1191.
Abstract

HATAKEYAMA T, Maeda T, Ide S
[A Case of Synchronous Primary Cancers of the Rectum and Bladder].
Gan To Kagaku Ryoho. 2025;52:1129-1130.
Abstract

SALZANO G, Digiacomo A, Dello Stritto G, Orsini A, et al
Artificial intelligence in bladder cancer management: a narrative review of diagnostic and surgical advances and current limitations.
Expert Rev Anticancer Ther. 2026 Jan 16. doi: 10.1080/14737140.2026.2619018.
Abstract

CHENG YT, Lu KH, Hong SY, Chen CH, et al
Particulate matter 2.5 promotes bladder cancer cell migration and invasion through the crosstalk between integrin-mediated MAPK/ERK and Wnt/beta-catenin pathways.
Part Fibre Toxicol. 2026 Jan 16. doi: 10.1186/s12989-025-00656.
Abstract

YANG J, Li X, Xie H, Guo J, et al
From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer.
World J Surg Oncol. 2026 Jan 17. doi: 10.1186/s12957-026-04196.
Abstract

KHAN JS, Lonergan PE, McLoughlin LC
Adherence to Bacille Calmette-Guerin protocol in the management of non-muscle invasive bladder cancer at St James's Hospital.
Ir J Med Sci. 2026 Jan 17. doi: 10.1007/s11845-025-04260.
Abstract

HAJIME T, Shiota M, Fukuchi G, Mutaguchi J, et al
Tumor Laterality Predicts Pelvic Lymph Node Metastasis Patterns in Bladder Cancer.
Ann Surg Oncol. 2026 Jan 16. doi: 10.1245/s10434-026-19088.
Abstract

SASAKI Y, Izumi K, Fukuta K, Kadoriku F, et al
Robot-Assisted Radical Cystectomy in the Very Elderly: A Propensity Score-Matched Comparison of Outcomes Between Patients Aged >/= 85 Versus 75-84 Years.
Geriatr Gerontol Int. 2026;26:e70346.
Abstract

MARAMI S, Tavakoli MH, Pashaki AS, Nikzad S, et al
Computational analysis of the impact of urine volume on magnetic nanoparticle hyperthermia in the treatment of non-muscle-invasive bladder cancer.
Eur J Pharm Biopharm. 2026 Jan 14:114992. doi: 10.1016/j.ejpb.2026.114992.
Abstract

DYRSKJOT L, Birkenkamp-Demtroder K, Nordentoft I, Strandgaard T, et al
ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial.
Ann Oncol. 2026 Jan 14:S0923-7534(26)00011-6. doi: 10.1016/j.annonc.2025.
Abstract

ZHANG Q, Zhang B, Niu J, Sun S, et al
POSTN+ cancer-associated fibroblasts promote bladder cancer progression via angiogenesis and immune modulation: an analysis based on single-cell Transcriptomics.
Integr Biol (Camb). 2026;18:zyag001.
Abstract

KAWAI T, Miki J, Taoka R, Saito R, et al
Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan.
Jpn J Clin Oncol. 2026 Jan 16:hyaf218. doi: 10.1093.
Abstract

LAERT J, Lupi Manso N, Franca de Santana T, Santos PO, et al
Pitfalls and Limitations of the Vesical Imaging-Reporting and Data System (VI-RADS): Challenges in the Multiparametric Magnetic Resonance Imaging (mpMRI) Assessment of Bladder Cancer.
Cureus. 2025;17:e99197.
Abstract

OKA R, Goto Y, Mikami K, Kato H, et al
Renal Granuloma Distinct From the Renal Pelvis Following Bacillus Calmette-Guerin Treatment for Bladder Cancer: A Case Report.
IJU Case Rep. 2026;9:e70141.
Abstract

DAI Y, Zhang X, Lin Q, Gu X, et al
Best evidence summary on gastrointestinal function recovery after radical cystectomy for bladder cancer.
Asia Pac J Oncol Nurs. 2025;13:100824.
Abstract

REYNARD M, Grobet-Jeandin E, Windisch O, Sebe P, et al
[Urology. Quality of life and safety : the new promises].
Rev Med Suisse. 2026;22:79-82.
Abstract

ZHANG J, Zheng L, Yu Z, Chen Y, et al
Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression.
Recent Pat Anticancer Drug Discov. 2026.
Abstract

FULORIA NK, Narain K, Biswas A, Gnanam P, et al
Tissue polypeptide antigen as a non-invasive bladder Cancer biomarker.
Clin Chim Acta. 2026 Jan 13:120843. doi: 10.1016/j.cca.2026.120843.
Abstract

CONTIERI R, Mollica V, Shariat SF, Pradere B, et al
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC).
Ann Oncol. 2026 Jan 13:S0923-7534(26)00012-8. doi: 10.1016/j.annonc.2026.
Abstract

SQUIRES P, Coutinho F, Tepsick JG, Rogiers A, et al
Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice.
Urol Oncol. 2026;44:110982.
Abstract

ILKI FY, Bulbul E, Topcu YK, Cinar O, et al
Comparison of intravesical Bacillus Calmette-Guerin and chemohyperthermia with mitomycin C in with high-risk non-muscle-invasive bladder cancer: a critical assesment focusing on the quality of life and adverse events.
BMC Urol. 2026 Jan 14. doi: 10.1186/s12894-025-02040.
Abstract

AL-SATTAR H, Ding H, Okoli O, Okoli S, et al
A multi-modal approach for decision making in bladder cancer.
Nat Rev Urol. 2026 Jan 14. doi: 10.1038/s41585-025-01122.
Abstract

MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
Reply to Matthias May, Ingmar Wolff, Sabine Brookman-May, and Maximilian Burger's Letter to the Editor re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Det
Eur Urol Oncol. 2026 Jan 13:S2588-9311(25)00344.
Abstract

ZHU M, Liu Y, Jia Y, Ren L, et al
Jujuboside A induces bladder cancer cell apoptosis by inhibiting ATP1A2-mediated mitochondrial energy metabolism regulation.
Cancer Biol Ther. 2026;27:2615418.
Abstract

CAO N, Cheng F
TSTA3 promotes the malignant progression of bladder cancer by regulating LAMP2 and MAPK signaling pathway-mediated epithelial-mesenchymal transition.
Genes Genomics. 2026 Jan 14. doi: 10.1007/s13258-025-01724.
Abstract

ARON S, Meagher M, Azari S, Baker B, et al
Beyond Sterility: the Urinary Microbiome in Bladder Cancer Carcinogenesis and Treatment.
Curr Urol Rep. 2026;27:8.
Abstract

DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
Morbi-mortality of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
J Robot Surg. 2026;20:173.
Abstract

GE T, Liu F, Cai M, Wu J, et al
Using transcriptomics and molecular docking to uncover the pharmacological targets and its associated biological mechanisms of paeoniflorigenone in treating bladder cancer.
Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04404.
Abstract

CHEN J, Liu X, Ren R, Yi R, et al
Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis.
Discov Oncol. 2026 Jan 14. doi: 10.1007/s12672-026-04440.
Abstract

DENIAUD C, Mesnard B, Bobet S, Perrouin-Verbe MA, et al
Oncologic outcomes of robot-assisted radical cystectomy for bladder carcinoma by urinary diversion type.
World J Urol. 2026;44:93.
Abstract

WU X, Zhou Y, Chen J, Zhang H, et al
A high-throughput photothermal aptasensing platform using MnO(2)@CuS nanoprobes for noninvasive detection of bladder cancer cells in simulated liquid biopsy.
Mikrochim Acta. 2026;193:88.
Abstract

INUI S, Ito S, Ueda T, Shiraishi T, et al
Efficacy and safety of cryoablation procedures using mouse models of bladder cancer.
Sci Rep. 2026 Jan 13. doi: 10.1038/s41598-026-35571.
Abstract

DADABHOY A, Doshi C, Zahir M, Ladi-Seyedian S, et al
Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series.
Urol Oncol. 2026;44:110984.
Abstract

MAN X, Zhang X, Dong A, He J, et al
Isolated Vaginal Recurrence of Urothelial Bladder Cancer on FDG PET/CT.
Clin Nucl Med. 2026 Jan 6. doi: 10.1097/RLU.0000000000006294.
Abstract

MJAESS G, Quackels T, Fantoni JC, Tricard T, et al
Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).
World J Urol. 2026;44:90.
Abstract

PEREZ-LONDONO A, Kaul S, Fleishman A, Korets R, et al
Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder.
World J Urol. 2026;44:91.
Abstract

ZHOU H, Peng S, Ling Z, Cai J, et al
Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.
World J Surg Oncol. 2026 Jan 12. doi: 10.1186/s12957-025-04175.
Abstract

AYDIN ME, Aykac A, Kaya C, Sungur M, et al
Comparative analysis of EAU, AUA, and NCCN guidelines for the management of non-muscle invasive bladder cancer.
BMC Urol. 2026 Jan 12. doi: 10.1186/s12894-026-02045.
Abstract

REGNIER S, Gabriel PE, Ouzaid I, Moschini M, et al
Second-look transurethral resection in high-grade Ta non-muscle invasive bladder cancer.
World J Urol. 2026;44:84.
Abstract

SUNGUR U, Bitkin A, Eksi M, Polat H, et al
Machine learning methods for predicting early recurrence in Ta stage bladder cancer and comparison with conventional statistical methods.
Minerva Urol Nephrol. 2026 Jan 12. doi: 10.23736/S2724-6051.25.06385.
Abstract

ZHANG F, Yang Y, Zhang R, Hu H, et al
Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer.
Chin J Cancer Res. 2025;37:1034-1057.
Abstract

Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4 [Retraction].
Am J Cancer Res. 2025;15:5395.
Abstract

HUANG H, Ye F, Liu T, Hong J, et al
Nano-Immunotherapy Synergizing Ferroptosis and STING Activation in Metastatic Bladder Cancer.
Cyborg Bionic Syst. 2026;7:0458.
Abstract

DE ALMEIDA MF, Rosa BG, Delechiave D, Annequin LF, et al
rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model.
Int J Biol Sci. 2026;22:713-730.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.
World J Urol. 2026;44:82.
Abstract

CHEN L, Jin C, Guo E, Liu F, et al
The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer.
J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70232.
Abstract

MUMUNI AN
Editorial for "The Performance of MR Cytometry Imaging in Differentiating High- and Low-Grade Bladder Cancer".
J Magn Reson Imaging. 2026 Jan 11. doi: 10.1002/jmri.70238.
Abstract

CHENG LH, Hsu CW, Yang PM, Liao TY, et al
Chemotherapy resistance of urinary bladder cancer mediated by a Notch and Wnt co-regulatory module of stemness.
Stem Cells. 2026 Jan 10:sxag002. doi: 10.1093.
Abstract

SYNESI G, Lewis R, Kilburn L, Bliss J, et al
Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review.
Trials. 2026;27:19.
Abstract

KAYRAKLIOGLU N, Zhang L, Cornelia Ding CK, Greenland NY, et al
Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
Hum Pathol. 2026;167:106005.
Abstract

FERNANDEZ O, Molina A, Anido-Herranz U, Alvarez C, et al
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.
Clin Transl Oncol. 2026;28:254-264.
Abstract

FERNANDEZ RODRIGUEZ P, Castillo Gazquez L, Tomas Alvarez S, Casals Seoane F, et al
Abdominal BCGitis with hepatosplenic and lymphatic involvement following intravesical therapy: a rare complication.
Rev Esp Enferm Dig. 2025;117:797-799.
Abstract

PARK I, Lee JL, Yoon S, Shin SJ, et al
A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03).
Cancer Res Treat. 2026;58:284-291.
Abstract

MEZEPO G, Khene ZE, Boustani J, Kleinclauss F, et al
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.
Eur Urol Oncol. 2026 Jan 22:S2588-9311(25)00343.
Abstract

GABRIEL PE, Xylinas E
The Future of Non-muscle-invasive Bladder Cancer: Towards a Molecular-Digital Paradigm for Personalized Management.
Eur Urol Focus. 2026 Jan 22:S2405-4569(26)00004.
Abstract

REIS LO
Bladder Cancer Immunotherapy in 2025: ALBAN, CREST, POTOMAC, and the Winner Is BCG!
Int Braz J Urol. 2026;52:e20259921.
Abstract

SUGAWARA D, Hatakeyama K, Konno M, Tozawa T, et al
Decision tree models combining Bi-parametric vesical imaging reporting and data system and apparent diffusion coefficient metrics for predicting muscle-invasive bladder cancer.
Abdom Radiol (NY). 2026 Jan 23. doi: 10.1007/s00261-026-05389.
Abstract

ZHAO Q, Gao S, Du Q, Liu Y, et al
[Expression of Concern] Long non?coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta?catenin signalling pathway.
Int J Mol Med. 2026;57:66.
Abstract

KUO WT, Pan CC, Liu YW, Chow NH, et al
Autophagy Plays a Suppressive Role in Bladder Tumor Formation in an Orthotopic Mouse Model and Bladder Cancer Patient Specimens.
Kaohsiung J Med Sci. 2026 Jan 23:e70179. doi: 10.1002/kjm2.70179.
Abstract

LIU L, Liang T, Huang G, Deng D, et al
Electroacupuncture in Combination with Bevacizumab Hydrogel Provides a Therapeutic Strategy for Bladder Cancer.
ACS Appl Mater Interfaces. 2026 Jan 22. doi: 10.1021/acsami.6c00404.
Abstract

Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China: Erratum.
Int J Surg. 2026;112:2201.
Abstract

DYRSKJOT L
ctDNA-guided treatment decisions in muscle-invasive bladder cancer.
Nat Rev Urol. 2026 Jan 22. doi: 10.1038/s41585-026-01125.
Abstract

HUANG Y, Chen C, Su M, Ye W, et al
TMEM11 promotes cisplatin resistance by inhibiting BNIP3-mediated mitophagy in bladder cancer.
Cancer Lett. 2026;641:218271.
Abstract

DO NT, Nguyen Tung L, Nguyen Cong D, Do MT, et al
Tumor Morphology as a Risk Factor for Muscle Invasiveness in Newly Diagnosed Bladder Cancer: A Stratified Analysis.
Asian Pac J Cancer Prev. 2026;27:151-156.
Abstract

STROJNY Z, Kanikowska A, Sikora W, Lewandowska M, et al
First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.
J Physiol Pharmacol. 2026;76:673-680.
Abstract

NAGUMO Y, Ye X, Shi T, Mathis BJ, et al
Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering.
Front Immunol. 2026;16:1629001.
Abstract

NUMATA Y, Ito H, Tatenuma T, Noguchi G, et al
[A CASE OF ACUTE EXACERBATION OF INTERSTITIAL PNEUMONIA AFTER ROBOT-ASSISTED TOTAL CYSTECTOMY].
Nihon Hinyokika Gakkai Zasshi. 2025;116:37-40.
Abstract

KURETAKE K, Minato A, Harada S, Fujimoto N, et al
[CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
Nihon Hinyokika Gakkai Zasshi. 2025;116:10-16.
Abstract

YAMADA R, Hayakawa N, Kikuchi E
[PERIOPERATIVE INCIDENCE OF VENOUS THROMBOEMBOLISM IN BLADDER CANCER PATIENTS TREATED BY OPEN RADICAL CYSTECTOMY].
Nihon Hinyokika Gakkai Zasshi. 2025;116:1-9.
Abstract

HUSSEIN AA, Klugman Y, Carlson J, Bhat TA, et al
Does the urinary microbiome reflect the bladder-cancer-associated microbiome? Characterizing the microbiome in urine and cancer tissue in bladder cancer.
Urol Oncol. 2026;44:110978.
Abstract

CALOUDAS AB, Haltom TM, Taylor JM
"It's Killed My Sex Life": Veteran Bladder Cancer Survivors' Perspectives on Sexual Problems and Intimacy.
Arch Sex Behav. 2026 Jan 21. doi: 10.1007/s10508-025-03364.
Abstract

SONG S MSC, Yang W MSc, Gao C MD
Comment on "The role of adjuvant chemotherapy after radical surgery in patients with lymph node-positive bladder cancer or locally advanced (pT3, pT4a) bladder cancer: a meta-analysis and systematic review".
Int J Surg. 2026 Jan 20. doi: 10.1097/JS9.0000000000004892.
Abstract

LI M, Liu X, Xue Y, Lu Y, et al
Integrative bulk and single-cell transcriptomic analysis reveals COL1A2-driven ECM remodeling and focal adhesion signaling associated with the transition from non-muscle-invasive to muscle-invasive bladder cancer.
Front Oncol. 2026;15:1716324.
Abstract

YAN B, Hu W, Li Y, Feng T, et al
Hyperthermic intravesical chemotherapy with gemcitabine versus Bacillus Calmette-Guerin in intermediate- and high-risk non-muscle-invasive bladder cancer.
Front Oncol. 2026;15:1715762.
Abstract

SONG F, Su S, Zhang X, Cao Y, et al
Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
Front Oncol. 2026;15:1710047.
Abstract

REDDY N, Lau K, Naman J, Lu K, et al
Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma.
Oncoimmunology. 2026;15:2611458.
Abstract

FAN D, Meng R, Han Y, Zhai Z, et al
Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates.
Medicine (Baltimore). 2026;105:e47176.
Abstract

CAI J, Jiao C, Xu Y, Zhang F, et al
Polarity protein Par3 deficiency promotes metastasis of bladder cancer via interaction of Ppp1r12c.
Biol Direct. 2026 Jan 20. doi: 10.1186/s13062-026-00727.
Abstract

LI Y, Zhou Z, Liu J, Cheng Z, et al
En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
World J Surg Oncol. 2026 Jan 20. doi: 10.1186/s12957-025-04172.
Abstract

JIANG M, Chen S, Ma H, Shi Y, et al
Intratumoral and Peritumoral Fat CT?Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.
Ann Surg Oncol. 2026 Jan 20. doi: 10.1245/s10434-025-18981.
Abstract

HE W, Wen Y, Qin H
LncRNA NPSR1-AS1 affects the malignant biological behavior of bladder cancer through miR-199a-3p and the clinical value of urine-derived lncRNA NPSR1-AS1.
Urol Oncol. 2026;44:110980.
Abstract

SHANG LL, Hu TL, Xiong S, Xu S, et al
Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer.
Eur J Med Chem. 2026;306:118581.
Abstract

STUART J, Zhuleku E, Mevius A, Squires P, et al
Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany.
Oncol Ther. 2026 Jan 20. doi: 10.1007/s40487-025-00413.
Abstract

HAYAKAWA N, Kikuchi E
[Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma].
Gan To Kagaku Ryoho. 2026;53:21-24.
Abstract

KITA Y
[Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer].
Gan To Kagaku Ryoho. 2026;53:16-20.
Abstract

SHIGEHISA R, Fukata S, Inoue K
[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].
Gan To Kagaku Ryoho. 2026;53:10-15.
Abstract

KAWAHARA T
[Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer].
Gan To Kagaku Ryoho. 2026;53:7-9.
Abstract

ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
Author Correction: Advances in the management of localized bladder cancers.
Nat Rev Clin Oncol. 2026 Jan 19. doi: 10.1038/s41571-026-01121.
Abstract

LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al
Development and external validation of a nomogram predicting cancer-specific mortality-free survival after trimodal therapy in muscle-invasive bladder cancer.
World J Urol. 2026;44:111.
Abstract

ZHAO Z, Zhao Z, Bu X, Wang M, et al
Added value of synthetic MRI in refining biparametric MRI VI-RADS for predicting muscle-invasive bladder cancer.
Abdom Radiol (NY). 2026 Jan 19. doi: 10.1007/s00261-025-05365.
Abstract

EL MJABBER R, Alami R, Aouzah F, Bezzari W, et al
Integrated Boost vs. Sequential Scheme in Volumetric Modulated Arc Therapy (VMAT) for Trimodal Bladder Cancer Therapy: A Comparative Study.
Cureus. 2025;17:e99438.
Abstract

KAUFMANN E, Aeppli S, Affentranger A, Arnold N, et al
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.
Bladder Cancer. 2026;12:23523735251410823.
Abstract

WU J, Jin S, Bai Q, Wang H, et al
Noninvasive Early Detection and Recurrence Monitoring for Non-Muscle-Invasive Bladder Cancer via Urine Tumor DNA: A Prospective Clinical Study.
MedComm (2020). 2026;7:e70592.
Abstract

YAMANAKA R, Miura K, Yamasaki N, Ogata S, et al
Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan.
Hypertens Res. 2026 Jan 19. doi: 10.1038/s41440-025-02535.
Abstract

LU L, Cheng H, Liu S, Tao Y, et al
TAK-901 targeted inhibition of EGFR activates transcription factor FOXO causing cell cycle arrest and apoptosis in bladder cancer.
Mol Cancer Ther. 2026 Jan 19. doi: 10.1158/1535-7163.MCT-25-0507.
Abstract

XU T, Wang K, Chen Y, Yu Y, et al
Adjuvant bacillus Calmette-Guerin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study.
Int Immunopharmacol. 2026;172:116186.
Abstract

RICHTERS A, Franken MD, Meijer RP, van der Heijden AG, et al
Treatments and survival outcomes of patients with synchronous and metachronous metastatic bladder cancer: A population-based nationwide cohort study.
Cancer Treat Res Commun. 2026;46:101099.
Abstract

MOHAMED T, Bani Irshid BA, Elhashamy H, Deameh MG, et al
Optimal duration of perioperative antibiotics in radical cystectomy and urinary diversion: a systematic review and meta-analysis.
Langenbecks Arch Surg. 2026;411:58.
Abstract

RICCIARDI G, Tralongo P, Pierconti F, Zuccala V, et al
Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.
Clin Genitourin Cancer. 2026;24:102478.
Abstract

KURIAN M, Mamtani R, Elghawy O, Nimgaonkar V, et al
Real-World Enfortumab Vedotin +/- Pembrolizumab Treatment-Based Toxicities and Associations With Survival in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2026;24:102474.
Abstract

WENG C, Deng H, Yang Z, Zeng X, et al
Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis.
J Transl Med. 2025;24:85.
Abstract

CARVALHO D, Pinto S, Sarmento B
Modeling the human bladder tissue using three dimensional in vitro approaches as a tool for drug screening platforms.
Acta Biomater. 2026;210:296-313.
Abstract

REVERDY T, Izarn F, Allignet B, Roubaud G, et al
Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.
Clin Genitourin Cancer. 2026;24:102465.
Abstract

COCA MEMBRIBES S, Szabados B, Powles T
Towards biomarker-driven therapies for urothelial carcinoma.
Nat Rev Clin Oncol. 2026;23:92-106.
Abstract

LITT HK, Mamtani R, Chow RD
Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction.
Urol Oncol. 2026;44:118.
Abstract

DOGRA S, Lee J, Siriruchatanon M, Gu Z, et al
Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.
Acad Radiol. 2026;33:472-481.
Abstract

CHEVILLE JC, Orme JJ, Gupta S, Lucien-Matteoni F, et al
Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes.
Mod Pathol. 2026;39:100928.
Abstract

MAREI A, Hohls M, Touloumtzidis A, Katoh M, et al
Metastasis of an urothelial carcinoma as rare cause of an AV-graft dysfunction in a transgender patient.
J Vasc Access. 2026;27:326-331.
Abstract

RAHMADI R, Mudhia Arisa Putri U, Herman H, Rachman W, et al
Case Report: Radical urethrectomy with partial cystectomy and bladder outlet reconstruction in giant female urethral adenocarcinoma infiltrating the bladder: A rare case report.
F1000Res. 2026;14:741.
Abstract

ZHANG X, Zong R, Sun Y, Chen N, et al
The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.
Oncol Res. 2026;34:21.
Abstract

FENG R, Zhang J, Tao Y, Hou J, et al
Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study.
Front Oncol. 2026;15:1644747.
Abstract

CHEN ST, Chang KS, Hou CP, Lin WY, et al
WISP1 is the stromal-secreting oncoprotein via paracrine downregulation of NDRG1, KAI1, and Maspin in human bladder cancer cells.
Transl Oncol. 2026;65:102680.
Abstract

NEBIOGLU A, Basaranoglu M, Bozlu M, Tek M, et al
Effects of dutasteride with Bacillus Calmette-Guerin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study.
BMC Urol. 2026 Jan 28. doi: 10.1186/s12894-026-02059.
Abstract

LU Q, Guo J, Xu Y, Cui Y, et al
RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.
Discov Oncol. 2026 Jan 28. doi: 10.1007/s12672-026-04514.
Abstract

MARCQ G, Dahm P, Maisch P
En-bloc resection: Evidence and uncertainty Re: Comparative effectiveness of en-bloc resection techniques vs. conventional transurethral resection for non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Can Urol Assoc J. 2026;20:E80-E81.
Abstract

SHIH YC, Wu CY, Huang SW, Tsai CY, et al
Multimodal Large Language Models for Cystoscopic Image Interpretation and Bladder Lesion Classification: Comparative Study.
J Med Internet Res. 2026;28:e87193.
Abstract

SHI WY, Liu KJ, Esfahani MS, Mach KE, et al
Field-effect-informed urine liquid biopsy for bladder cancer.
Cell. 2026 Jan 27:S0092-8674(25)01503-X. doi: 10.1016/j.cell.2025.
Abstract

SCHERRER M, Brunaiova L, Furrer M, John H, et al
How safe is teaching radical cystectomy? : Results from the prospective Swiss society of urology database.
World J Urol. 2026;44:133.
Abstract

HE Y, Xie J, Zhong S, Zhan C, et al
A Deep Learning-Generated Mixed Tumor-Stroma Ratio for Prognostic Stratification and Multi-omics Profiling in Bladder Cancer.
Research (Wash D C). 2026;9:1053.
Abstract

HU H, Huang J, Ma L, Zhang S, et al
Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China.
Front Urol. 2026;5:1713128.
Abstract

PAN S, Cui W, Lin J, Wang Z, et al
The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.
Front Immunol. 2026;16:1716230.
Abstract

FRYD ND, Albertsen N, Bernth-Andersen S, Ernst A, et al
The GreenBladder Study: Early Detection of Bladder Cancer in Greenland Using a Urinary Biomarker.
J Clin Med. 2026;15:761.
Abstract

KLATTE T, Bold F, Dengler J, de Martino M, et al
Trends in the Management of Bladder Cancer with Emphasis on Frailty: A Nationwide Analysis of More Than 49,000 Patients from a German Hospital Network.
Life (Basel). 2026;16:169.
Abstract

ALQAISI O, Tai P, Storme G
Specialized Nursing-Led Interventions for Bladder Cancer Management: A Scoping Review of Evidence and Clinical Outcomes.
Medicina (Kaunas). 2026;62:185.
Abstract

NEBIOGLU A, Turhan A, Basaranoglu M, Bozlu M, et al
Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis.
Medicina (Kaunas). 2025;62:51.
Abstract

COJOCARU I, Guliciuc M, Cojocaru E, Serban C, et al
A Review of the Latest Evidence on Prognostic Factors in Locally Advanced and Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Medicina (Kaunas). 2025;62:46.
Abstract

JIANG H, Chen Y, Zeng X, Yang R, et al
The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment.
Int J Mol Sci. 2026;27:596.
Abstract

MOHAMED AA, AbdulAzeem Y, Almudaifer AI, ZainEldin H, et al
Explainable Computational Imaging for Precision Oncology: An Interpretable Deep Learning Framework for Bladder Cancer Histopathology Diagnosis.
Bioengineering (Basel). 2025;13:4.
Abstract

NAN Z, Zhao W, Li S, Yue C, et al
Unequal Progress in Early-Onset Bladder Cancer Control: Global Trends, Socioeconomic Disparities, and Policy Efficiency from 1990 to 2021.
Healthcare (Basel). 2026;14:193.
Abstract

CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
Unveiling the Female Factor: Gender-Based Differences in Outcomes and Survival Following Radical Cystectomy for Bladder Cancer.
Cancers (Basel). 2026;18:308.
Abstract

PACKIAM VT, Ghodoussipour S, Konety BR, Ahmadi H, et al
Impact of Computational Histology AI Biomarkers on Clinical Management Decisions in Non-Muscle Invasive Bladder Cancer: A Multi-Center Real-World Study.
Cancers (Basel). 2026;18:249.
Abstract

PITOUT A, Mazeaud C, Blondeau A, Salleron J, et al
Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.
Cancers (Basel). 2026;18:222.
Abstract

SANDHU K, Hopkins DT, Newton M, Sathianathen N, et al
Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.
Cancers (Basel). 2026;18:189.
Abstract

PIRES I, Files R
Silent Threats: A Narrative Review of Urinary Bladder Cancer in Dogs and Cats-Epidemiology and Risk Factors.
Animals (Basel). 2026;16:217.
Abstract

MIKI J, Kimura S, Urabe F, Atsuta M, et al
Optimizing pelvic lymph node dissection in bladder cancer: obturator focus, pN1 prognosis, and sentinel node feasibility.
Int J Clin Oncol. 2026 Jan 27. doi: 10.1007/s10147-026-02969.
Abstract

SHEN L, Yu C, Wu Y, Chen H, et al
NFIB suppresses cell migration, invasion and EMT of bladder cancer through the PI3K-AKT signaling pathway.
Cytotechnology. 2026;78:33.
Abstract

QIU M, Zhang S, Liang J, Chen G, et al
Prolyl 4-Hydroxylase Beta Peptide Promotes Invasion, Migration, and Epithelial-Mesenchymal Transition through Activation of the Claudin-1/ AMPK/TGF-beta1 Pathway in Bladder Cancer Cells.
Protein Pept Lett. 2026 Jan 22. doi: 10.2174/0109298665418763251124051527.
Abstract

ZENG D, Liu B, Deng F, Wang Y, et al
Multidimensional liquid biopsy in bladder cancer: advances in circulating tumor cells, circulating tumor DNA, exosomes, and metabolomics.
Oncologist. 2026;31:oyaf409.
Abstract

SILVA TA, Viana LG, Carvalho VM, Bertolla RP, et al
Proteomic Profiling of Non-Muscle Invasive Bladder Cancer Reveals Potential Biomarkers for Recurrence and Progression Risk.
J Proteome Res. 2026 Jan 26. doi: 10.1021/acs.jproteome.5c00486.
Abstract

WANG X, Preston A, Aning J, Loizou M, et al
Early Detection of Bladder Cancer Using Advanced Feature Engineering and Swarm Intelligence Optimization on EHRs.
IEEE Trans Biomed Eng. 2026;PP.
Abstract

KARKEET RM, Sayed-Ahmed MM, Ghaly S, Farouk M, et al
Comprehensive Evaluation of Bacillus Calmette-Guerin therapy in Non-muscle invasive bladder cancer Egyptian patients: a retrospective cohort study.
J Egypt Natl Canc Inst. 2026;38:2.
Abstract

ZHANG WW, Qu HR, Du XS, Sun SJ, et al
SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
Cell Oncol (Dordr). 2026;49:30.
Abstract

NAPPI A, Crocetto F, Conforti P, Sagliocchi S, et al
Cell-free RNA profiling uncovers non-canonical circulating D2 transcript elevation in Bladder Cancer plasma.
J Liq Biopsy. 2026;11:100454.
Abstract

WANG P, Deng J, Wu S
Modeling and validation of serum miR-18a and miR-122 levels as predictors of recurrence after laparoscopic radical cystectomy procedure for bladder cancer based on nomogram model.
Front Oncol. 2026;15:1579873.
Abstract

HARMON JF, Santos E, Johnson-Pais TL, Leach RJ, et al
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population.
Bladder Cancer. 2026;12:23523735261417401.
Abstract

SU X, Yu H, Zhang M, Zeng K, et al
A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
Front Mol Biosci. 2026;12:1716130.
Abstract

YUAN Z, Situ M, Ye Y, Zhang J, et al
Dissecting the role of KLF5: from tumor progression to immune interactions with emphasis on glioma and bladder cancer.
Front Immunol. 2026;16:1730356.
Abstract

CHAN CC, Lee MJ, Su J, Su JJ, et al
Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.
Pharmacol Res Perspect. 2026;14:e70212.
Abstract

CHEN Y, Lao M, Shen M, Wang Z, et al
TMIGD2 in Bladder Cancer: A Bioinformatics and Experimental Approach to Understanding its Prognostic and Therapeutic Potential.
Curr Top Med Chem. 2026 Jan 15. doi: 10.2174/0115680266414071251126071447.
Abstract

CHEN Y, Zhu H, Lao M, Ding G, et al
Exploring ZPLD1 as a Prognostic Indicator and Therapeutic Target in Bladder Cancer.
Curr Med Chem. 2026 Jan 15. doi: 10.2174/0109298673413898251122184011.
Abstract

FANG Q, You C, Xiao X, Yang W, et al
Targeting the WWP2-ASPP2 axis overcomes cisplatin resistance by inhibiting the mevalonate pathway in TP53-mutant bladder cancer.
Int J Biol Macromol. 2026;343.
Abstract

LUTY M, Szydlak R, Pabijan J, Ovreeide IH, et al
Identification of glycosylation-related changes in migratory and mechanical properties of bladder cancer cells.
Biosens Bioelectron. 2026;298:118410.
Abstract

CHEN M, Zheng L, Huang D, Wang S, et al
RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.
Int J Biol Macromol. 2026 Jan 22:150142. doi: 10.1016/j.ijbiomac.2026.150142.
Abstract

CHEN Q, Wu R, Zhang C, Xie J, et al
Efficacy and safety of tislelizumab plus intravesical chemotherapy in recurrent high-risk non-muscle-invasive bladder cancer: A retrospective single-center real-world study.
Urol Oncol. 2026;44:110988.
Abstract

KLUTH M, Plage H, Furlano K, Hofbauer S, et al
PTEN Deletions Are Associated With Tumor Progression But Unrelated to Patient Prognosis in Muscle-Invasive Urothelial Bladder Carcinomas: A Large Multi-Center Validation Study on 2710 Urothelial Bladder Carcinomas.
Genes Chromosomes Cancer. 2026;65:e70105.
Abstract

CHEN WW, Wu B, Wen X
Causal association between socioeconomic disparities and tumors of the urinary system: A Mendelian randomization study.
Medicine (Baltimore). 2026;105:e47216.
Abstract

WANG Y, Bhandary P, Moore JH, Li X, et al
Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.
Biol Sex Differ. 2026 Jan 23. doi: 10.1186/s13293-026-00829.
Abstract

BENTSEN L, Lund-Jacobsen T, Jakobsen CB, Larsen FM, et al
Shared Decision-Making in Curative Uro-Oncology: A Systematic Review.
Semin Oncol Nurs. 2026;42:152116.
Abstract

SONG T, He W, Yuan Q, Xia S, et al
ADAM12-programmed ECM-CAF remodeling activates PI3K-AKT and enforces an immune-excluded microenvironment to drive bladder cancer progression and therapy resistance.
Cell Signal. 2026 Feb 4:112398. doi: 10.1016/j.cellsig.2026.112398.
Abstract

LABROY M, Chabaud S, Durand M, Fourquaux I, et al
Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.
Transl Oncol. 2026;65:102687.
Abstract

WANG Y, Ni H, Dong S, Shang Y, et al
Environmental Dose MEOHP Promotes Bladder Cancer Progress through Hybrid EMT Mechanism: Based on the Adverse Outcome Pathway.
Environ Sci Technol. 2026 Feb 6. doi: 10.1021/acs.est.5c08003.
Abstract

JIANG M, Sun C, Wang B, Huang Q, et al
Analysis of the molecular mechanism underlying di(2-ethylhexyl) phthalate-induced bladder carcinogenesis via network toxicology and molecular docking approaches: An observational study.
Medicine (Baltimore). 2026;105:e47378.
Abstract

TAKADA H, Ikeda M, Tanaka R, Samejima N, et al
Prognostic effect of preoperative albumin-to-globulin ratio in patients with non-metastatic bladder cancer undergoing radical cystectomy.
Oncology. 2026 Feb 6:1-20. doi: 10.1159/000550892.
Abstract

MEHMUD I, Zhang Y, Wu S, Zhang S, et al
Oncological Safety of Bladder Preservation in Elderly Patients with Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Feb 6. doi: 10.1245/s10434-025-19064.
Abstract

BOLENZ C, Zengerling F, Kubler H, Hahn O, et al
[Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?].
Urologie. 2026 Feb 6. doi: 10.1007/s00120-026-02774.
Abstract

MOJICA W, Izydorczak A, Wood T, Hsu J, et al
A Novel Method to Generate Analyte-Specific Specimens for Multi-Omic Studies of Primary Bladder Cancer.
Biopreserv Biobank. 2026 Feb 6:19475535251394594. doi: 10.1177/19475535251394594
Abstract

NING W, Chang P, Zheng J, Chen W, et al
Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.
Front Immunol. 2026;16:1684597.
Abstract

GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
medRxiv [Preprint]. 2026 Jan 16:2026.01.14.26344033.
Abstract

JALAL H, Kang SK, Alarid-Escudero F, Chrysanthopoulou SA, et al
Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.
medRxiv [Preprint]. 2026 Jan 30:2026.01.27.26344939.
Abstract

MAK KS, Efstathiou JA
Tipping the Scales for Bladder Cancer: Weighing Differences in Quality of Life After Cystectomy Versus Trimodality Therapy.
Int J Radiat Oncol Biol Phys. 2026;124:651-653.
Abstract

NABIYOUNI F, Chiou PZ
Enhancing urine cytopathology with artificial intelligence: a systematic review.
Am J Clin Pathol. 2026;165:aqaf135.
Abstract

LIU N, Xing L, Chen H, Chen S, et al
Sequential dilatation of two balloons and double D-J stents for therapy of ureteroenteral anastomotic stricture in patients following radical cystectomy and Bricker urinary diversion.
Afr Health Sci. 2025;25:334-342.
Abstract

CHEN K, Su H, Pei F, Chen X, et al
KNTC1 initiates a KNTC1/E2F8/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer.
J Exp Clin Cancer Res. 2026 Feb 4. doi: 10.1186/s13046-026-03651.
Abstract

HSIEH YC, Li CF, Ho CH, Huang SK, et al
Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma.
Appl Immunohistochem Mol Morphol. 2026 Feb 5. doi: 10.1097/PAI.0000000000001307.
Abstract

JIN H
Comment on "adjuvant bacillus Calmette-Gu'erin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naive high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study".
Int Immunopharmacol. 2026;173:116312.
Abstract

XU G, Li Y, Peng S, Zhao W, et al
Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer.
Cell Rep. 2026;45:116941.
Abstract

LIU Q, Lu X, He C, Chen J, et al
A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19122.
Abstract

WANG Y, Guo S, Zeng J, Feng W, et al
Prognostic Significance of Lymph Node Ratio for Overall Survival in Patients with Lymph Node-Positive Bladder Cancer Post-Radical Cystectomy and Chemotherapy: A Multicenter Cohort Analysis.
Ann Surg Oncol. 2026 Feb 4. doi: 10.1245/s10434-026-19090.
Abstract

DE FELICE M, Tammaro M, Caterino M, Nacca V, et al
Fulminant Fournier gangrene in bladder cancer: case report and review of the literature.
Eur Rev Med Pharmacol Sci. 2026;30:46-50.
Abstract

OZTURK YUZDEMIR K, User IR, Ozcan HN, Orhan D, et al
Pediatric inflammatory myofibroblastic tumor of the urinary bladder: a rare case report and treatment approach.
Turk J Pediatr. 2025;67:920-926.
Abstract

SOMA T, Takemura K, Toide M, Ito M, et al
Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure: a systematic review.
BMJ Oncol. 2026;5:e000753.
Abstract

YIN Y, Qin Z, Zhou H, Wu Y, et al
Ultrasound Responsive Mn/Se-Nanozyme as PANoptosis Initiators for Bladder Cancer Immunotherapy.
Adv Healthc Mater. 2026 Feb 3:e04808. doi: 10.1002/adhm.202504808.
Abstract

HAJIME T, Shiota M, Matsumoto T, Mutaguchi J, et al
ASO Author Reflections: Tumor Laterality as a Key Determinant of Pelvic Lymph Node Dissection Strategy in Bladder Cancer.
Ann Surg Oncol. 2026 Feb 3. doi: 10.1245/s10434-026-19200.
Abstract

TANG X, Liu L, Gao M, Duan P, et al
Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer.
Sci Rep. 2026 Feb 3. doi: 10.1038/s41598-026-38219.
Abstract

SHEN C, Liu C, Hu D, Ge H, et al
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer.
J Immunother Cancer. 2026;14:e013809.
Abstract

ZHANG H, Liu Y, Huang W, Li Y, et al
Mediator complex subunit 8 promotes bladder cancer progression via Stearoyl-CoA desaturase.
Cell Mol Life Sci. 2026 Feb 3. doi: 10.1007/s00018-026-06083.
Abstract

WANG Z, He W, Wang M, Hua M, et al
Integrated multicenter single-cell atlas of bladder cancer reveals tumor heterogeneity associated with immunotherapy.
Int J Surg. 2026 Feb 3. doi: 10.1097/JS9.0000000000003830.
Abstract

MIKHAIL AS, Gurram S, Valera VA, Haemmerich D, et al
Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.
Int J Hyperthermia. 2026;43:2615462.
Abstract

VAN DE MERBEL AF, van der Mark MH, Hensen LCM, van den Wollenberg DJM, et al
Improved oncolytic and immunostimulatory activity of the spontaneous jin-3 reovirus mutant in preclinical bladder cancer models.
Mol Ther Oncol. 2026;34:201128.
Abstract

YOUSSEF M, Nasseredine B, Amine Z, Amine S, et al
Psoas metastasis mimicking abscess in untreated muscle-invasive bladder cancer: A diagnostic pitfall.
Radiol Case Rep. 2026;21:1554-1558.
Abstract

MENG X, Su CY, Yang Z
Editorial Comment on: "Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative Analysis and Optimization Study of Multiple Large Language Models" by Li et al.
J Endourol. 2026 Feb 2:8927790251387369. doi: 10.1177/08927790251387369.
Abstract

YAMAMOTO S, Fukata S, Shimasaki S, Kurano Y, et al
Clinical Outcomes Following Transurethral Laser Ablation with Topical Versus General or Spinal Anesthesia for Non-Muscle-Invasive Bladder Cancer: A Japanese Single-Center Pilot Study.
Photodiagnosis Photodyn Ther. 2026 Jan 31:105376.
Abstract

YOKOYAMA T, Kobayashi H, Horiguchi A, Miyai K, et al
A Case of Primary Bladder Neuroendocrine Carcinoma With Urethral Invasion Following Radical Prostatectomy.
Asian J Endosc Surg. 2026;19:e70251.
Abstract

ZHANG M, Zhou Y
Sexual distress in patients after radical cystectomy for bladder cancer: a qualitative study.
Support Care Cancer. 2026;34:151.
Abstract

WANG X, Jin L, Zou X, Zhu A, et al
ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.
J Pharm Anal. 2026;16:101519.
Abstract

LIU Z, Zhou C, Xu W, Zhang D, et al
Polyarginine Peptide R11-Actin Interaction Induces a Domino Effect on Cytoskeleton Remodeling to Suppress Bladder Cancer Metastasis.
Research (Wash D C). 2026;9:1109.
Abstract

ZHANG M, Lin L, Xu H, Su X, et al
A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer.
Front Mol Biosci. 2026;12:1722809.
Abstract

EL OMRI G, Houssaini OI, Rachid M, Houry Y, et al
Non-functional bladder paraganglioma in a young patient: conservative management by transurethral resection and diagnostic challenges.
Pan Afr Med J. 2025;52:105.
Abstract

WANG Y, Yuan H, Zhang Y, Zhang Y, et al
Intravesical folate-conjugated hydroxyethyl starch micelles for pH-triggered co-delivery of epirubicin and TLR7 agonist toward synergistic chemoimmunotherapy of bladder cancer.
Mater Today Bio. 2026;37:102835.
Abstract

YU K, Sun J, Zhang J, Shi Y, et al
Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer.
Cancer Lett. 2026;642:218282.
Abstract

ZHAO J, Zhao J, Huang W, Lin W, et al
Decoding metabolic reprogramming heterogeneity across bladder cancer stages using single-cell and spatial multi-omics approaches.
Comput Methods Programs Biomed. 2026;277:109261.
Abstract

LI D, Lu J, Zhu R, Sun X, et al
Ad-VT oncolytic adenovirus suppresses bladder cancer via cAMP-dependent AMPK-Raptor activation and G2/M arrest.
Tumour Virus Res. 2026;21:200337.
Abstract

CHEN Z, Chen X, Xie R, Huang M, et al
DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression.
Mol Ther. 2026 Jan 30:S1525-0016(26)00036-5. doi: 10.1016/j.ymthe.2026.
Abstract

DU A, Zhou Y, Deng X, Yuan D, et al
DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6.
Mol Cancer. 2026 Jan 30. doi: 10.1186/s12943-025-02560.
Abstract

DAY E, Bizzarri FP, Mackenzie C, Szabados B, et al
Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.
Nat Rev Urol. 2026 Jan 30. doi: 10.1038/s41585-026-01124.
Abstract

MORIKAWA T, Hamamoto S, Tasaki Y, Ishikawa D, et al
Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.
Asian J Endosc Surg. 2026;19:e70248.
Abstract

ZHOU J, Jiang X, Liu Q, Xia HA, et al
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results.
Cancer Metastasis Rev. 2026;45:7.
Abstract

BOURGI A, Rusch E, Bruyere F
Water-Related Exposures And Bladder Cancer Risk: A Comprehensive Epidemiological Review.
Cancer Epidemiol Biomarkers Prev. 2026.
Abstract

AY A, Alkanli N, Atli E, Gurkan H, et al
Investigation of the Correlation Between Selected miRNAs, Proinflammatory Cytokines, and Serum Trace Elements in Bladder Cancer Development and Progression.
Curr Issues Mol Biol. 2025;48:53.
Abstract

RIAZ IB, Humayun MA, Khaki AR, Hussain SA, et al
Treatment Sequencing in Advanced Urothelial Cancer.
Drugs. 2026;86:203-215.
Abstract

ZARZYCKA M, Kotula-Balak M, Gil D
Inhibiting autophagy enhances anti-cancer properties of sulforaphane.
Sci Rep. 2026;16:5296.
Abstract

KIELBIK A, Hellwich E, Bahlinger V, Sowa P, et al
Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells.
Commun Biol. 2025;9:153.
Abstract

KATSUMATA Y, Yamamoto S, Iwata H, Kuroiwa H, et al
Agent-specific differences in sustained intraoperative hypotension during oral 5-Aminolevulinic acid-guided transurethral resection of bladder tumor: A retrospective observational study.
Photodiagnosis Photodyn Ther. 2026;57:105319.
Abstract

MANOHARAN M, Raja Iyub MJ, Zhang Y, Prabhakar P, et al
Development of a Multivariable Machine Learning Model for the Prediction of Postoperative Ileus After Radical Cystectomy.
J Surg Oncol. 2026;133:226-232.
Abstract

WANG J, Zhao X, Jiang XL, Liu G, et al
Construction and Validation of a Prognostic Survival Prediction Model for NMIBC Patients Undergoing Radical Cystectomy.
Cancer Invest. 2026;44:156-173.
Abstract

NIHARIKA, Tripathi S, Singhai A, Goel A, et al
Clinical correlates of key autophagic markers, ATG4B, LC3 and p62 in urothelial carcinoma of bladder patients.
Tissue Cell. 2026;99:103240.
Abstract

TEOH JY, Bracco FM, Wong JH, Liu AQ, et al
A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial.
Eur Urol Oncol. 2026;9:111-115.
Abstract

KONG L, Yang G, Weng B, Wen Z, et al
Early Detection of Chemotherapy-Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium ((2)H) Metabolic Imaging: in Vitro and in Vivo Assessments.
Adv Sci (Weinh). 2026;13:e14614.
Abstract

RAGGI D, Crupi E, Pederzoli F, Martini A, et al
HER2 and urothelial carcinoma: current understanding and future directions.
Nat Rev Urol. 2026;23:110-132.
Abstract

HARLE V, Agrawal YO
Development of Novel Intravesical Formulation for Bladder Retention Targeting Bladder Disorders.
Curr Drug Targets. 2025;26:903-920.
Abstract

FILON M, Schmidt B
The Future of Novel Antibody-drug Conjugates in Localized Urothelial Cancer.
Eur Urol Focus. 2026;12:34-37.
Abstract

CHATZKEL J, Linscott J, Daniel Grass G, Li R, et al
Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies.
Eur Urol Focus. 2026;12:38-40.
Abstract

WU K, Liu X, Zhang J, Wang X, et al
Mechanisms and implications of epithelial cell plasticity in the bladder.
Nat Rev Urol. 2026;23:70-88.
Abstract

PYRGIDIS N, Schulz GB, Scilipoti P, Pellegrino F, et al
The Role of Salvage Cystectomy After Prior Trimodality Therapy: A Multinational Match-paired Analysis.
Eur Urol Focus. 2026;12:88-95.
Abstract

ROBBRECHT DGJ, Salhi Y, Martens JWM, Aarts MJB, et al
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.
Eur Urol Oncol. 2026;9:7-11.
Abstract

CHEN J, Fu S, Yu J, Tang Q, et al
Modified Glasgow prognostic score as a marker for predicting outcomes in patients with either bladder and prostate cancer : A systematic review and meta-analysis.
Oncology. 2025 Mar 28:1-20. doi: 10.1159/000545001.
Abstract

HILSER T, Darr C, Bedke J, Ivanyi P, et al
Treatment of Advanced or Metastatic Urothelial Cancer.
Oncol Res Treat. 2026;49.
Abstract

DOMIAN N, Mlynarczyk G, Kasacka I
Analysis of CacyBP/SIP, ERK1/2, and p38 Expression in Low- and High-Grade Papillary Urothelial Carcinoma.
Cancer Med. 2026;15:e71649.
Abstract

RYOO SW, Choi BY, Son SY, Lee JH, et al
Occupational Exposure to Welding Fumes and the Risk of Bladder Cancer: A Systematic Review and Meta-Analysis.
Am J Ind Med. 2026 Feb 15. doi: 10.1002/ajim.70062.
Abstract

TUNCEKIN A, Aktas Y
The role of systemic inflammatory and prognostic indices in diabetic patients with non-muscle invasive bladder cancer receiving BCG therapy.
Actas Urol Esp (Engl Ed). 2026 Feb 12:501925. doi: 10.1016/j.acuroe.2026.501925.
Abstract

MICHALET M, Ronchin P, Reynaud T, Demogeot N, et al
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.
Radiother Oncol. 2026;217:111443.
Abstract

GAO M, Li C, Li W, Xie J, et al
White-to-brown adipose switching promotes bladder cancer progression.
Neoplasia. 2026;73:101282.
Abstract

SCILIPOTI P, Rosiello G, Santangelo A, Viti A, et al
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.
Urol Oncol. 2026;44:111007.
Abstract

ELSAWY AA, Laymon M, Ezzat O, Mansour I, et al
Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial.
Urol Oncol. 2026;44:111006.
Abstract

SONG YX, Xia XL, Wu ZM, Yao Y, et al
Integration of bulk and single-cell transcriptomic sequencing reveals the neutrophil heterogeneity in bladder cancer and establishes a prognostic model.
Discov Oncol. 2026 Feb 14. doi: 10.1007/s12672-026-04559.
Abstract

DINCER E, Ozkaptan O, Canakci C, Ipek OM, et al
The Modified Frailty Index-5 as a Predictor of Postoperative Complications Following Radical Cystectomy.
J Coll Physicians Surg Pak. 2026;36:258-262.
Abstract

LIU Y, Duan L, Zhu M, Zhou Z, et al
Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis.
BMC Complement Med Ther. 2026 Feb 13. doi: 10.1186/s12906-026-05279.
Abstract

WAN E, Wade C, Sathe A, Ferguson JE 3rd, et al
Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.
Curr Urol Rep. 2026;27:13.
Abstract

SJODAHL G, Eriksson P, Hoglund M
Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014.
Eur Urol Focus. 2026 Feb 12:S2405-4569(26)00012.
Abstract

LIU J, Luo Y, Chen L, Xiong W, et al
Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer.
Biochim Biophys Acta Mol Basis Dis. 2026;1872:168192.
Abstract

HUANG X, Chen R, Guo Z, Song C, et al
Intensive nursing interventions for post-treatment anxiety and depression in bladder cancer: A systematic review and meta-analysis.
Support Care Cancer. 2026;34:195.
Abstract

LIU ZX, Shi YY, Zhou DS, Chen SN, et al
Role of MED15 in Enhancing EMT and Metastasis in Bladder Cancer Through YAP1 Stabilization.
FASEB J. 2026;40:e71558.
Abstract

LI A, Zhao K, Wang T, Shi G, et al
Transcriptome and single-cell RNA sequencing analysis with 101 machine learning combinations and experimental verification reveals the mechanism of action of mannose metabolism in bladder cancer.
Front Immunol. 2026;17:1710823.
Abstract

ZHANG G, Wang L, Zhao G, Huang Y, et al
Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15.
Research (Wash D C). 2026;9:1134.
Abstract

SHANGGUAN W, Li W, Huang W, Wu J, et al
FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization.
Adv Sci (Weinh). 2026 Feb 13:e23256. doi: 10.1002/advs.202523256.
Abstract

BUTT UA, De Biase D
Correction: Butt, U.A.; De Biase, D. The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer. Int. J. Mol. Sci. 2025, 26, 10558.
Int J Mol Sci. 2026;27:1521.
Abstract

RUTZ J, Grein T, Laqua M, Benhassine K, et al
Natural Isothiocyanates Block Adhesion and Invasion of Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Molecules. 2026;31:555.
Abstract

KOCAK T, Ozbek YD, Bodur M, Yesil S, et al
Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.
J Clin Med. 2026;15:1247.
Abstract

PENG Y, Wang H, Chen H, Jin Z, et al
SAPCD2 Drives Bladder Cancer Progression by Stabilizing TANK and Engaging a CREB-PLAGL2 Feedback Loop to Sustain MAPK Signaling.
Cancers (Basel). 2026;18:535.
Abstract

DEL GIUDICE F, Santarelli V, Khan A, Gad M, et al
Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions.
Cancers (Basel). 2026;18:500.
Abstract

WANG X, Guo J, Zhang R, Dong Y, et al
Hypoxia-inducible factor 1alpha exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion.
Sci Rep. 2026 Feb 12. doi: 10.1038/s41598-026-39635.
Abstract

KUANG J, An Y, Zhang X, He Z, et al
Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.
Biochim Biophys Acta Rev Cancer. 2026 Feb 10:189558.
Abstract

YUTKIN V, Maalouf N, Gur C, Zini A, et al
Targeting Bladder Cancer with Inactivated Uropathogenic E. coli: A Novel Alternative to BCG Immunotherapy.
Cells. 2026;15:229.
Abstract

YANG Y, Wang F, Ning W, Ding Y, et al
CircRNA_103809/miR-516a/FBXL18 contributes to stemness and gemcitabine resistance of bladder cancer cells.
Arch Med Sci. 2025;21:2766-2782.
Abstract

XU X, Gu W, Zakeri MA, Chen YH, et al
No genetic causal links detected between antihypertensive medications and bladder cancer: insights from a trans-ancestry, drug-target Mendelian randomization analysis.
Arch Med Sci. 2025;21:2856-2863.
Abstract

KUMAR P, Alarid-Escudero F, Chiddarwar TV, Garibay-Trevino DU, et al
Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis.
medRxiv [Preprint]. 2026 Feb 2:2026.01.30.26344972.
Abstract

LOCATELLI I, Lorenzoni M, Venegoni C, Di Coste A, et al
PD1-IL2v expands and induces effector CD8(+) TILs, but not Tregs, in the BCG treated orthotopic non-muscle invasive bladder cancer model.
J Exp Clin Cancer Res. 2026 Feb 11. doi: 10.1186/s13046-026-03667.
Abstract

UTLU A, Aksakalli T, Celik F, Cinislioglu AE, et al
HALP score as an independent prognostic biomarker for recurrence and progression in non-muscle-invasive bladder cancer: A retrospective cohort study.
Surg Oncol. 2026;65:102357.
Abstract

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
N Engl J Med. 2026;394:728.
Abstract

KUNG TC, Jiang YH, Kuo HC
Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan.
Tzu Chi Med J. 2025;38:83-89.
Abstract

LI L, Li Q, Liu J, Wang Y, et al
Integrated single-cell and spatial transcriptomics combined with whole-exome sequencing reveal key hub genes and epithelial heterogeneity in bladder cancer.
Front Oncol. 2026;15:1748105.
Abstract

CASALE P, Hurle R, Buffi NM, Lughezzani G, et al
Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.
Curr Urol. 2026;20:117-124.
Abstract

SUN X, Jia D, Song X, Jiang Y, et al
Revealing the function and mechanism of piRNA-related genes in bladder cancer through single-cell sequencing and methylation analyses and construction of prognostic features based on consensus clustering.
Curr Urol. 2026;20:101-116.
Abstract

HARLAND N, Reitnauer LE, Amend B, Bahlinger V, et al
Significant differences in CD276 (B7H3) expression between female and male bladder cancer tissue samples: An exploratory study.
Curr Urol. 2026;20:125-126.
Abstract

LIN N, Chen L, Zhang Y, Yang Y, et al
Retraction Note: KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment.
Sci Rep. 2026;16:5741.
Abstract

AYDOGDU C, McSweeney ST, Packiam VT, Bukavina L, et al
ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.
Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19129.
Abstract

SORENSEN EE, Frydendahl A, Rasmussen MH, Nordentoft I, et al
Molecular residual disease assessment in colorectal and bladder cancer by somatic structural variant analysis of cell-free DNA whole-genome sequencing data.
J Transl Med. 2026 Feb 9. doi: 10.1186/s12967-026-07762.
Abstract

TAO L, Zhao T, Xu Y, Chen W, et al
Integrative multi-cohort analysis identifies urinary microbiota as non-invasive biomarkers of bladder cancer.
BMC Microbiol. 2026 Feb 9. doi: 10.1186/s12866-026-04829.
Abstract

LIN Z, Zhao K, Wang S, Liu J, et al
Oncogenic and immunological roles of LAMP5 across cancers and its potential utility in bladder cancer.
Apoptosis. 2026;31:65.
Abstract

FUKUSHIMA H, Yoshida S, Yajima S, Chen W, et al
A multi?criteria decision analysis comparing robot?assisted, laparoscopic, and open radical cystectomy using large-scale Japanese nationwide databases.
J Robot Surg. 2026;20:230.
Abstract

LEEDER M, Leucht K, Marx M, Grimm MO, et al
[Treatment of non-muscle-invasive bladder cancer].
Urologie. 2026 Feb 9. doi: 10.1007/s00120-026-02781.
Abstract

GAO C, Cao X, Miao L, Chen W, et al
lncRNA FENDRR as a Prognostic Biomarker and Regulator of Bladder Cancer Progression via the miR-18a-5p/ESR1 Axis.
J Environ Pathol Toxicol Oncol. 2026;45:1-12.
Abstract

LIU Q, Huang J
ASO Author Reflections: Augmenting Contrast-Enhanced Ultrasound: A Quantitative Approach to Predict Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-026-19236.
Abstract

MANIVASAGAM SS, Kassim A, Raman JD
Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.
Future Sci OA. 2026;12:2622297.
Abstract

SHIBEL PE, Elyamany AM, El Shorbagy G, Abd Elmaogod EA, et al
Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.
Asian Pac J Cancer Prev. 2026;27:667-675.
Abstract

ABDEL-HAKEEM SS, Abdel-Hakeem SS, Kamal FMM
Crosstalk between ZEB1 expression and CD163+ Tumor-Associated Macrophages in Muscle-Invasive Urothelial Carcinoma.
Asian Pac J Cancer Prev. 2026;27:499-507.
Abstract

CARAPITO A, Sousa TV, Teixeira-Marques A, Henrique R, et al
Urinary Metabolomics Identifies Lactate as a Biomarker for Bladder Cancer Detection and Progression.
Mol Omics. 2026 Feb 9:aaiag004. doi: 10.1093.
Abstract

ROLLIN P, Pluskwa B, Artru E, Le Vaslot T, et al
BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4(+) Th1 responses.
iScience. 2026;29:114676.
Abstract

LONCA L, Beniac P, Necsulescu A, Teixeira-Guerra D, et al
Robot-Assisted Cystoprostatectomy for Muscle-Invasive Bladder Cancer in a Patient With a Prior Simultaneous Pancreas-Kidney Transplantation.
Case Rep Transplant. 2026;2026:9534770.
Abstract

ZHANG X, Su S, Liu L, Song F, et al
Preoperative fibrinogen-to-lymphocyte ratio as a prognostic biomarker for non-muscle-invasive bladder cancer.
Front Oncol. 2026;16:1707696.
Abstract

SOOD A, Martini A, Rudzinski JK, Tholomier C, et al
Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer.
bioRxiv [Preprint]. 2026 Jan 26:2026.01.23.701130.
Abstract

JIA B, Rao B, Chen R, Cui K, et al
Overview of tumor-resident intratumoral microbiota in human bladder cancer.
Transl Androl Urol. 2026;15:19.
Abstract

ZHOU H, Ge Z, Lin S, Wu Y, et al
Application of serum miRNA panel in bladder cancer detection.
Transl Androl Urol. 2026;15:23.
Abstract

ZHAO L, Yang JW, Chen SY, Wang L, et al
Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
Transl Androl Urol. 2026;15:29.
Abstract

ZHANG X, Fu Y, Du Y, Xiong W, et al
CCT5 as a candidate biomarker in bladder cancer: functional validation and mechanistic clues.
Am J Cancer Res. 2026;16:51-69.
Abstract

RANJITH N, Khan PA, Koppolu S, Pavani S, et al
Impact of lifestyle factors on recurrence rates in non-muscle invasive bladder cancer: A case-control study.
Bioinformation. 2025;21:4025-4027.
Abstract

WANG Y, Liu L, Li M
Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:2031-2037.
Abstract

ABU-GHANEM Y, Laszkiewicz J, Chan HT, Krajewski W, et al
Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: A systematic review.
Crit Rev Oncol Hematol. 2026;220:105192.
Abstract

KLINGLMAIR G, Lutz M, Telia T, van Creij NCH, et al
Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.
J Nutr Health Aging. 2026;30:100805.
Abstract

XIE H, Liao T, Tang H, Ban C, et al
The GFPT2/O-GlcNAcylation/c-Myc axis promotes bladder cancer progression.
J Transl Med. 2026 Feb 7. doi: 10.1186/s12967-026-07811.
Abstract

CONTIERI R, Paciotti M, Uleri A, Saita A, et al
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial.
Eur Urol Oncol. 2026 Feb 6:S2588-9311(26)00031-3. doi: 10.1016/j.euo.2026.
Abstract

DEMIGNE JB, Ferber E, Rodrigues M, Flippot R, et al
[Perioperative durvalumab with neoadjuvant cisplatine-gemcitabine chemotherapy in localized muscle-invasive bladder cancer].
Bull Cancer. 2026 Feb 6:S0007-4551(26)00056-1. doi: 10.1016/j.bulcan.2025.
Abstract

GARG T, Negron-Candelario S, Miller H, Demirsoy S, et al
Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.
Urol Oncol. 2026;44:110996.
Abstract

QIN M, Xie G, Xie H, Lin B, et al
Development and validation of a novel senescence-associated gene signature for prediction of survival and endocrine-disrupting chemicals in bladder cancer.
Discov Oncol. 2026 Feb 7. doi: 10.1007/s12672-026-04611.
Abstract

CHEN H, Peng Y, Ji Z, Dong J, et al
SPP1(+) Macrophage-POSTN(+) Fibroblast-Endothelial Triad Dictates Immunotherapy Response in Bladder Cancer.
FASEB J. 2026;40:e71546.
Abstract

KONG Y, Li Y, An M, Luo Y, et al
Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
J Exp Clin Cancer Res. 2026;45:39.
Abstract

ZHANG Q, Guo Y, Lin F, Zuo Y, et al
?CT image-derived radiomics predicts molecular subtypes in bladder urothelial carcinoma: validation of a non-invasive classification strategy.
Sci Rep. 2026;16:6016.
Abstract

HERCZEG BT, Sudar A, Ortutay R, Agoston P, et al
Risk estimations of radiation induced malignancies in rectum and bladder following radiotherapy of prostate carcinoma.
Phys Med. 2026;142:105714.
Abstract

JENDEBERG J, Bjorkman A, Dahlman P, Eklof H, et al
Computed tomography urography in macroscopic hematuria: a retrospective study with implications for standard care pathway.
Acta Radiol. 2026;67:227-236.
Abstract

ZHU Y, Jiang S, Shi Y, Wang S, et al
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Ann Oncol. 2026;37:378-387.
Abstract

IWATANI K, Urabe F, Mori K, Nakano J, et al
Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study.
Jpn J Clin Oncol. 2026;56:234-240.
Abstract

YAJIMA S, Yoshida S, Chen W, Hirose K, et al
Bayesian reanalysis of avelumab maintenance therapy in Asian and Japanese patients with advanced urothelial carcinoma: evidence from the JAVELIN Bladder 100 trial.
Jpn J Clin Oncol. 2026;56:216-220.
Abstract

ESCOBAR D, Doshi C, Zahir M, Daneshmand S, et al
Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.
Urologie. 2026;65:162-170.
Abstract

BAHLBURG H, Rausch P, Tully KH, Berg S, et al
Psychosocial distress after radical prostatectomy, radical cystectomy, or (partial) nephrectomy - a comprehensive analysis of 4,290 German cancer patients during the COVID-19 pandemic.
J Cancer Surviv. 2026;20:181-188.
Abstract

LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al
Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological Outcomes.
Eur Urol Oncol. 2026 Feb 19:S2588-9311(26)00042.
Abstract

GAO J, Pan Y, Cheng Q, Wang S, et al
USP43 promotes lymphatic metastasis of bladder cancer by regulation of ZBTB7A.
Cell Signal. 2026 Feb 18:112433. doi: 10.1016/j.cellsig.2026.112433.
Abstract

JONAS K, Moser T, Heitzer E
Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC.
Cell. 2026;189:995-997.
Abstract

ZHANG H, Han S, Su Z, Zheng Z, et al
Single-cell transcriptomic analysis and machine learning identify ATAD3A as a key gene that stabilizes mitochondrial-endoplasmic reticulum membranes, promoting bladder cancer progression.
J Transl Med. 2026 Feb 20. doi: 10.1186/s12967-026-07857.
Abstract

KWON J, Jeon J, Lee HS, Jeon S, et al
Effects of Radiation Therapy on the Incidence of Bladder Cancer and Rectal Cancer in Patients with Prostate Cancer: A Nationwide Nested Case-Control Study in Korean Population.
World J Mens Health. 2026 Jan 15. doi: 10.5534/wjmh.250298.
Abstract

LAHIRI A, Chowdhury S, Goel S, Assif Iqbal S, et al
Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study.
HPB (Oxford). 2026 Feb 2:S1365-182X(26)00016-X. doi: 10.1016/j.hpb.2026.
Abstract

CAUSIO FA, De Vita V, Nappi A, Sawaya M, et al
Survival Prediction in Patients With Bladder Cancer Undergoing Radical Cystectomy Using a Machine Learning Algorithm: Retrospective Single-Center Study.
JMIR Perioper Med. 2026;9:e86666.
Abstract

KATO M, Matsue T, Yamamoto S, Yukimatsu N, et al
Clinical impact of carboplatin-based neoadjuvant chemotherapy: lack of benefit and surgical delay in muscle-invasive bladder cancer.
Jpn J Clin Oncol. 2026 Feb 19:hyag027. doi: 10.1093.
Abstract

ZHANG P, Xiong W, Wang K, Zhao X, et al
Copper-based architectures for bladder cancer therapy: mechanistic insights, progress and prospects.
Nanoscale. 2026 Feb 19. doi: 10.1039/d5nr04072.
Abstract

LIU X, Chen Z, Lu Y, Wu Y, et al
Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder Cancer.
Front Microbiol. 2026;17:1756107.
Abstract

OKADA N, Kimura H, Ozaki M, Tamura M, et al
Risk Factor of Persistent Hypotension Associated with 5-Aminolevulinic Acid: A Single-Institution Retrospective Study.
Biol Pharm Bull. 2026;49:335-340.
Abstract

SUN Y, Tong H, Zhao G, Wu L, et al
Nutrient Deprivation Promotes Bladder Cancer Metastasis through Beclin-1 Deacetylation-Mediated Autophagy Activation.
Cancer Lett. 2026 Feb 16:218337. doi: 10.1016/j.canlet.2026.218337.
Abstract

VULSTEKE C, Adra N, Danchaivijitr P, Sabadash M, et al
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
N Engl J Med. 2026 Feb 18. doi: 10.1056/NEJMoa2511674.
Abstract

XU C, Dong Y, Li J, Liao X, et al
Integrating machine learning and mendelian randomization for identifying genetic biomarkers in bladder cancer: implications for early diagnosis and targeted therapies.
Int J Surg. 2025 Dec 3. doi: 10.1097/JS9.0000000000003833.
Abstract

HU J, Zhu Y, Wang G, Dai H, et al
SNW1 promotes lymphatic metastasis in bladder cancer by modulating SRPK1 splicing.
iScience. 2026;29:114811.
Abstract

HUANG X, Meng Y, Song J, Zhu Y, et al
KNSTRN knockdown impairs autophagy flux to inhibit bladder cancer progression.
iScience. 2026;29:114734.
Abstract

ZHANG J, Wang J, Hu X, Jia W, et al
Biomimetic hydrogel for the construction of patient-derived bladder cancer organoids with aggressive growth.
iScience. 2026;29:114786.
Abstract

HINLEY J, Baker SC, Mason AS, Kyriazis G, et al
Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers.
Life Sci Alliance. 2026;9:e202503427.
Abstract

KOHLER J, Buck L, Hugelmann K, Incesu RB, et al
Chronological and biological age stratify survival after robot-assisted radical cystectomy for bladder cancer: a pragmatic age-ECOG risk score.
World J Urol. 2026;44:178.
Abstract

ACCETTO T, Strasek Smrdel K, Taskovska M, Starcic Erjavec M, et al
Negative-control-anchored urinary microbiome profiling with absolute 16S quantification: a pilot study in newly diagnosed, treatment-naive bladder cancer and healthy individuals.
FEMS Microbiol Lett. 2026 Feb 17:fnag020. doi: 10.1093.
Abstract

LIU Q, Lu X, He C, Chen J, et al
Correction: A Novel Model for Muscle-Invasive Bladder Cancer Diagnosis Using Contrast-Enhanced Ultrasound.
Ann Surg Oncol. 2026 Feb 16. doi: 10.1245/s10434-026-19331.
Abstract

LI H, Long G, Hu L, Wang Q, et al
Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: a multicenter, prospective single-arm cohort.
Photodiagnosis Photodyn Ther. 2026 Feb 14:105396.
Abstract

CRESTANI B, Tamborrino V, Bertolo R, Antonelli A, et al
Balancing maternal and fetal safety in non-muscle-invasive bladder cancer: report of our experience.
Minerva Urol Nephrol. 2026;78:155-157.
Abstract

LAMBERTINI L, Saladino M, DI Maida F, Grosso AA, et al
Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.
Minerva Urol Nephrol. 2026;78:118-126.
Abstract

CHEN KY, Jones MK, Ghosal S, Ignozzi GP, et al
Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.
BJUI Compass. 2026;7:e70135.
Abstract

FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.
BJUI Compass. 2026;7:e70173.
Abstract

INDRASWARI MT, Rahman F, Hamid ARAH, Mochtar CA, et al
Psychological distress among bladder cancer patients: A systematic review.
Urol Ann. 2026;18:10-17.
Abstract

SONG F, Su S, Zhang X, Cao Y, et al
A nomogram based on the red cell distribution width to lymphocyte ratio as a prognostic tool for non-muscle-invasive bladder cancer: a retrospective study.
Front Oncol. 2026;16:1728821.
Abstract

PAN S, Zhu H, Yin R, Lin J, et al
Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.
Front Cell Infect Microbiol. 2026;15:1727550.
Abstract

BASAR M, Yol C, Chen JF, Al-Ahmadie H, et al
Micropapillary Urothelial Carcinoma: A Review and Update.
Adv Anat Pathol. 2026;33:e1-e8.
Abstract

DAS M, Rath S, Gorepatti R, Dash R, et al
Microbiome-linked transcriptomic signatures in NMIBC: Toward personalized uro-oncology.
Urol Oncol. 2026;44:110977.
Abstract

QU M, Wei J, Mo J, Chen J, et al
Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy.
Urol Oncol. 2026;44:110970.
Abstract

WEIR S, Murgas KA, Froehlich M, Nash M, et al
Urothelial cell carcinoma of the bladder in pediatric patients: A comparison with adults from the National Cancer Database.
J Pediatr Urol. 2026;22:105677.
Abstract

WEBER TD, Gershman B, Wang L, Rosen S, et al
Rapid evaluation of muscularis propria in transurethral resection of bladder tumour specimens using non-linear microscopy (NLM).
J Clin Pathol. 2026;79:186-191.
Abstract

LANGE F, Gaisa NT, Bolenz C, Klumper N, et al
[Pathological Risk Stratification of Non-Muscle-Invasive and Muscle-Invasive Urothelial Carcinoma for Optimal Therapeutic Decision-Making].
Aktuelle Urol. 2026;57:52-59.
Abstract

NIEGISCH G, Zschabitz S, Klumper N, Eckstein M, et al
[Current and future treatment stratification of metastatic urothelial carcinoma: a great opportunity for true precision oncology].
Aktuelle Urol. 2026;57:46-51.
Abstract

SRIVASTAVA A, Trivedi S, Kumar U, Singh Y, et al
Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naive non-muscle-invasive bladder cancer.
BJU Int. 2025 Dec 23. doi: 10.1111/bju.70126.
Abstract

MENNES J, Akand M, Benijts R, Baekelandt L, et al
Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?
BJU Int. 2025 Dec 23. doi: 10.1111/bju.70096.
Abstract

PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
BJU Int. 2026;137:323-331.
Abstract

SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
BJU Int. 2026;137:270-281.
Abstract

SILVANI C, Santangelo A, Considine J, Tylecki A, et al
Area deprivation and cancer-specific mortality in non-muscle-invasive bladder cancer: a statewide analysis.
BJU Int. 2026 Jan 20. doi: 10.1111/bju.70151.
Abstract

ABOU CHAKRA M, McElree IM, Mott SL, O'Donnell MA, et al
Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
BJU Int. 2026 Jan 19. doi: 10.1111/bju.70149.
Abstract

AMER ML, Amer AR, Elnasharty SF, Homouda AA, et al
Impact of perioperative nutrition on recovery after radical cystectomy: a randomised trial.
BJU Int. 2026;137:536-546.
Abstract

BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
Cancer. 2026;132:e70220.
Abstract

LUO W, Wang Y, Wang H, Ji YA, et al
CCL5hi-CD4+ T cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer.
Cancer Res. 2026 Feb 18. doi: 10.1158/0008-5472.CAN-25-2220.
Abstract

CHEVRIER S, Richard C, Adotevi O, Ayyoub M, et al
Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.
Clin Cancer Res. 2026 Jan 13. doi: 10.1158/1078-0432.CCR-25-2306.
Abstract

EPSTEIN IB, Odogiyon A, Berg S, Otani Y, et al
ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.
Clin Cancer Res. 2026 Jan 26. doi: 10.1158/1078-0432.CCR-25-3712.
Abstract

GUERCIO BJ, Pietzak EJ, Ravichandran V, Chen JF, et al
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Clin Cancer Res. 2026 Feb 2. doi: 10.1158/1078-0432.CCR-25-3771.
Abstract

MIRKHESHTI N, Kpormegbey DE, Weinstock C, Gao X, et al
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.
Clin Cancer Res. 2026 Feb 12. doi: 10.1158/1078-0432.CCR-25-3609.
Abstract

KATIMS AB, White C, Alam SM, Farha M, et al
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2026 Feb 9. doi: 10.1158/1078-0432.CCR-25-3395.
Abstract

LOPEZ-BELTRAN A, Cimadamore A, Blanca A, Montironi R, et al
Sarcomatoid urothelial carcinoma: advances and challenges.
Curr Opin Urol. 2026;36:147-154.
Abstract

COMPERAT E
Biomarkers and testing in pathology.
Curr Opin Urol. 2026;36:212-216.
Abstract

ERTOY-BAYDAR D
Histologic subtypes of urothelial carcinoma: an update.
Curr Opin Urol. 2026;36:138-146.
Abstract

REIS H, Szarvas T, Paner GP
Urachal cancer: a clinical, diagnostic, and therapeutic update.
Curr Opin Urol. 2026;36:155-160.
Abstract

ST-LAURENT MP, Black PC
The challenge of bladder preservation in muscle invasive bladder cancer: key concepts and future directions.
Curr Opin Urol. 2026 Jan 30. doi: 10.1097/MOU.0000000000001369.
Abstract

PERRI D, Roche JB, Petrut B, Bozzini G, et al
Bladder diverticula management - conservative and surgical outcomes: a narrative review from EAU endourology.
Curr Opin Urol. 2026;36:79-85.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
Eur Urol. 2025 Dec 31:S0302-2838(25)04877-8. doi: 10.1016/j.eururo.2025.
Abstract

GALLAGHER K, MacLennan S, Bhatt N, Clement K, et al
RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery.
Eur Urol. 2025 Dec 10:S0302-2838(25)04736-0. doi: 10.1016/j.eururo.2025.09.4174.
Abstract

FILHO AM, Briganti A, Jemal A, Bray F, et al
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
Eur Urol. 2025 Dec 19:S0302-2838(25)04864-X. doi: 10.1016/j.eururo.2025.
Abstract

HERR H
Re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial. Eur Urol.
Eur Urol. 2026 Jan 12:S0302-2838(25)04897-3. doi: 10.1016/j.eururo.2025.
Abstract

ROVIELLO G, Vascotto IA, Antonuzzo L
Re: ctDNA-guided Adjuvant Atezolizumab in Muscle-invasive Bladder Cancer.
Eur Urol. 2026 Jan 12:S0302-2838(26)00008-4. doi: 10.1016/j.eururo.2026.
Abstract

KITAMURA H, Tsukamoto T, Kakehi Y, Mizusawa J, et al
Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.
Eur Urol. 2026 Jan 21:S0302-2838(26)00014-X. doi: 10.1016/j.eururo.2026.
Abstract

GARMAN TS, Kates MR
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
Eur Urol. 2026 Jan 19:S0302-2838(26)00016-3. doi: 10.1016/j.eururo.2026.
Abstract

PICHLER R, Subiela JD, Scilipoti P, Rehder P, et al
Regional Node-positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings.
Eur Urol. 2026 Jan 19:S0302-2838(26)00019-9. doi: 10.1016/j.eururo.2026.
Abstract

NAGUMO Y, Kimura T, Ishikawa H, Sekino Y, et al
Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
Eur Urol. 2026 Jan 17:S0302-2838(25)04872-9. doi: 10.1016/j.eururo.2025.
Abstract

CABRERA C, Buisan O, Servian P
Reply to the Harry Herr's Letter to the Editor re: Oscar Buisan, Pol Servian, Sonia Pedreno-Lopez, et al. A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Canc
Eur Urol. 2026 Jan 23:S0302-2838(26)00018-7. doi: 10.1016/j.eururo.2026.
Abstract

PICHLER R, Subiela JD, Guerrero-Ramos F
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2
Eur Urol. 2026 Feb 4:S0302-2838(26)00054-0. doi: 10.1016/j.eururo.2026.
Abstract

GABRIEL PE, Xylinas E
Re: Ding Ding, Lei Qian, Di Jin, et al. Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study. Eur Urol 2026;89:93-5.
Eur Urol. 2026 Feb 3:S0302-2838(26)00030-8. doi: 10.1016/j.eururo.2026.
Abstract

BABJUK M
Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial.
Eur Urol. 2026 Feb 3:S0302-2838(26)00027-8. doi: 10.1016/j.eururo.2026.
Abstract

HAYNE D, Zhang AY, Thomas H, Krieger L, et al
Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
Eur Urol. 2026 Feb 2:S0302-2838(26)00015-1. doi: 10.1016/j.eururo.2026.
Abstract

TATEO V, Basile G, Giannatempo P, de Jong JJ, et al
Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Eur Urol. 2026 Feb 2:S0302-2838(26)00022-9. doi: 10.1016/j.eururo.2026.
Abstract

MYERS AA, Talwar R, Duan Z, Hensley P, et al
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guerin-unresponsive Carcinoma in Situ of the Bladder.
Eur Urol. 2026;89:151-162.
Abstract

SCILIPOTI P, Zaurito P, Longoni M, Colecchia M, et al
Corrigendum to "Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guerin (BCG) in BCG-naive High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials" [Eur. Urol. (2025)].
Eur Urol. 2026 Feb 17:S0302-2838(26)00063-1. doi: 10.1016/j.eururo.2026.
Abstract

NIEDERSUESS-BEKE D, Mayrhofer K, Krauter J, Franke J, et al
Enfortumab vedotin plus pembrolizumab in treatment-naive metastatic urothelial carcinoma patients: An Austrian real-world analysis.
Int J Cancer. 2026;158:1654-1665.
Abstract

DU J, Shen H, Zeng T, Liu W, et al
Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next?generation antibody-drug conjugates (Review).
Int J Oncol. 2026;68:28.
Abstract

TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
Abstract

FIORENTINO V
Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
Abstract

CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
Abstract

IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
Int J Urol. 2026;33:e70341.
Abstract

HIRATA H
Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
Int J Urol. 2026;33:e70343.
Abstract

FUJITA N
Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
Int J Urol. 2026;33:e70358.
Abstract

SOMA T, Tanaka H, Nakamura Y, Numao N, et al
Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
Int J Urol. 2026;33:e70329.
Abstract

ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
Int J Urol. 2026;33:e70330.
Abstract

SHIMIZU S, Osawa T, Sato M, Yamada S, et al
Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
Int J Urol. 2026;33:e70364.
Abstract

FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
Int J Urol. 2026;33:e70283.
Abstract

ABE Y, Taoka R, Kaji A, Harada S, et al
Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
Int J Urol. 2026;33:e70365.
Abstract

YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
Int J Urol. 2026;33:e70380.
Abstract

KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
Int J Urol. 2026;33:e70386.
Abstract

CHAI Y, Zhou Y, Peng H, Jiang Y, et al
Comparative efficacy of hyperthermic chemotherapy and BCG instillation in non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Int Urol Nephrol. 2026 Jan 11. doi: 10.1007/s11255-026-05008.
Abstract

OZDEN SB, Bulbul E, Ilki Y, Vural A, et al
Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.
Int Urol Nephrol. 2026 Jan 26. doi: 10.1007/s11255-026-05021.
Abstract

AYKAC A, Kaya C, Sungur M, Aydin ME, et al
Holmium laser en?bloc vs bipolar and conventional monopolar TURBT for non?muscle?invasive bladder cancer.
Int Urol Nephrol. 2026 Jan 24. doi: 10.1007/s11255-026-05023.
Abstract

REZAEE ME, Higgins MI, Su ZT, Sepehri S, et al
Results from the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.
J Urol. 2026 Feb 9:101097JU0000000000004983. doi: 10.1097/JU.0000000000004983.
Abstract

ANDERSON CB, Sfakianos JP
Circulating Tumor DNA in Bladder Cancer: A New Treatment Paradigm?
J Urol. 2026;215:256-257.
Abstract

LAZAROVICH A, Nusbaum DJ, Agarwal PK, Modi PK, et al
Clinical Trial Design for Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential.
J Urol. 2026 Feb 11:101097JU0000000000004960. doi: 10.1097/JU.0000000000004960.
Abstract

ZHAO D, Khatri VM, Nakashima JY, Chadha J, et al
Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy.
J Urol. 2026;215:305-315.
Abstract

ELIAS R, Aragaki AK, Hoffman-Censits JH, Hahn NM, et al
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
J Urol. 2026;215:294-304.
Abstract

RITCH C, Anderson CB
Cystoscopic Fulguration for Patients with Recurrent Low-Grade Bladder Cancer.
J Urol. 2026 Feb 18:101097JU0000000000004974. doi: 10.1097/JU.0000000000004974.
Abstract

ZHANG S, Li T, Li D, Yin Y, et al
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
J Urol. 2026 Feb 17:101097JU0000000000004993. doi: 10.1097/JU.0000000000004993.
Abstract

WANG J, Wang J, Meng L, Wang X, et al
Interstitial cystitis-related gene CCDC8 accelerates tumorigenesis by participating in CUL7-mediated degradation of P53 in bladder cancer.
Oncogene. 2026 Feb 5. doi: 10.1038/s41388-026-03688.
Abstract

PAN XW, Li L, Huang Y, Huang H, et al
[Corrigendum] Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
Oncol Rep. 2026;55:51.
Abstract

TJIAMAN MP, Zaidan MZ, Ausath ZF, Putri AT, et al
Quality of Life and Postoperative Complications of Single- or Bilateral-stoma Cutaneous Ureterostomy Compared to Ileal Conduit After Radical Cystectomy: A Systematic Review and Meta-analysis.
Urology. 2026;207:287-292.
Abstract

HEARD JR, Pagano I, Rosser C, Tan WS, et al
Hematuria Cancer Risk Score in Combination With Oncuria-Detect for Patients Undergoing Evaluation for Hematuria.
Urology. 2026;207:178-183.
Abstract

SIGUENCIA F, Heard J, Smith SM, Pagano I, et al
Diagnostic performance of urinary biomarker tests in detecting bladder cancer: A systematic review, meta-analysis, and network meta-analysis.
Urology. 2026 Feb 4:S0090-4295(26)00074-9. doi: 10.1016/j.urology.2026.
Abstract

SMITH AB, Gore JL, Chisolm S, Squires P, et al
Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
Urology. 2026 Feb 11:S0090-4295(26)00092-0. doi: 10.1016/j.urology.2026.
Abstract

HJORT PB, Hyldgaard JM, Young-Halvorsen K, Husch T, et al
Association between Photodynamic diagnosis and risk of recurrence and progression in BCG-treated non-muscle invasive bladder cancer patients: a nationwide follow-up study.
Urology. 2026 Feb 10:S0090-4295(26)00091-9. doi: 10.1016/j.urology.2026.
Abstract

APONTE-COLON DA, Wilcox Vanden Berg R, Tua-Caraccia R, Kim JK, et al
Clinical Characteristics, Recurrence, and Survival for Children and Young Adults With Urothelial Cancer: A Systematic Review.
Urology. 2026;208:135-141.
Abstract

YANG IN, Liang CA, Wu CC, Xu QS, et al
Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
BMC Cancer. 2025;25:1900.
Abstract

RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
Abstract

ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
Abstract

OSAKA K, Kishida T, Umemoto S, Karashima T, et al
Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
Abstract

ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
Abstract

GAO X, Yu Y, Sun J, Zhao H, et al
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy.
PLoS Biol. 2026;24:e3003647.
Abstract

FENG C, Chen G, Shu Y, Chen J, et al
Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
PLoS One. 2026;21:e0342162.
Abstract

SHEN J, Zhao Z, Li Z, Wang R, et al
Bladder cancer-induced CVD mortality: Role of CAPG protein.
PLoS One. 2026;21:e0338101.
Abstract

DARJI S, Qu F, Henager M, Prasad A, et al
Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
Proc Natl Acad Sci U S A. 2026;123:e2502486122.
Abstract

GALSKY MD, Izadmehr S, Yu M, Curtis SD, et al
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
Proc Natl Acad Sci U S A. 2026;123:e2533449123.
Abstract

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum

;